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ABSTRACT OF DISSERTATION

HIGH DOSE SIMVASTATIN AS A POTENTIAL ANTICANCER THERAPY IN
LEUKEMIA PATIENTS

Simvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor that is used for the treatment of hyperlipidemia. Simvastatin has recently been
studied for its potential use in cancer therapy. In-vitro studies have shown that
simvastatin displays anticancer activity, but at concentrations unlikely to be achieved in
patients being receiving typical antihyperlipidemic treatment doses. Thus, several
clinical trials were conducted to study the tolerability of high dose statins in cancer
patients. The maximum tolerated dose of simvastatin was determined to be 15
mg/kg/day, 25-fold higher than a typical dose. However, it is not known if simvastatin
plasma concentrations can reach those found to be effective in-vitro. In this context, we
initiated a clinical study to determine the pharmacokinetics of high dose simvastatin in
patients with chronic lymphocytic leukemia. For this purpose, an LC-MS/MS method was
developed and validated for the quantitation of simvastatin and its acid form in plasma
and peripheral blood mononuclear cells obtained from CLL patients. Results show that
simvastatin concentrations were dose proportional relative to the antihyperlipidemic
doses, but lower than those required for in-vitro cytotoxicity against cancer cells. These
findings demonstrate that the in-vitro effective concentrations of simvastatin are not
achievable clinically, which might explain the limited effectiveness of high dose
simvastatin in this study and in previous clinical trials. In view of these data, the use of
simvastatin as a sole therapy in cancer treatment was not encouraging and led us to
examine the use in combination with other anticancer drugs.
After screening several chemotherapeutic agents in combination with
simvastatin, we showed that tipifarnib (a farnesyltransferase inhibitor) interacts
synergistically in several leukemia cell lines. Mechanistically we showed that simvastatin
augments the cytotoxicity of tipifarnib by disrupting the localization of RAS in the cell
membrane and by subsequent deactivation of the ERK pathway. Consistent with this
observation, drug treatment led to the induction of apoptosis through the caspase
cascade activation and the cleaved PARP upregulation. Notably, this synergistic effect

was observed at clinically achievable concentrations of simvastatin and tipifarnib. Thus,
the effectiveness of this combination should be explored further in future clinical studies.
KEYWORDS: Simvastatin, Leukemia, LC-MS/MS, Pharmacokinetics, Tipifarnib
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Chapter 1 : Introduction
A. Background
Statins have become well established as safe and effective drugs in the treatment
of hypercholesterolemia. The beneficial effects of statins in primary and secondary
prevention of cardiovascular diseases were demonstrated in several clinical trials, such
as Scandinavian Simvastatin Survival Study (4S) [1], Long-term Intervention with
Pravastatin in Ischemia Disease (LIPID) [2], Cholesterol and Recurrent Events (CARE)
[3] , West of Scotland Coronary Prevention Study (WOSCOPS) [4], Air Force/Texas
Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) [5] and the Heart
Protection Study (HPS) [6]. Statins mediate their effect through the inhibition of the 3hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase, an enzyme of the
mevalonate pathway. In a rate limiting process this enzyme catalyzes the conversion of
HMG CoA to mevalonate, the precursor of cholesterol [7, 8]. Thus, statins exert their
therapeutic effect primarily by decreasing the intracellular hepatic cholesterol levels and
by upregulating the hepatic LDL receptor expression, which results in an increase of LDL
cholesterol hepatic uptake and substantial decline in plasma LDL cholesterol levels [7,
8].
The statin family is composed of eight members that are naturally derived or
chemically synthesized (Figure 1.1). Lovastatin, simvastatin, and pravastatin are
naturally derived from fungal fermentation, whereas fluvastatin, atorvastatin, cerivastatin,
rosuvastatin and pitavastatin are synthetically derived. Cerivastatin was withdrawn from
the market in August 2001 due to risk of serious rhabdomyolysis. All statins possess a
common structural characteristic which is an HMG-CoA like moiety that enables statins
to compete with HMG-CoA on the enzyme active site. In all of the statins, this side chain
moiety exists in an open ring (active, acid) form which is responsible for binding the
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HMG CoA reductase active site. However, lovastatin and simvastatin are present in a
lactone prodrug form which undergoes hydrolysis in vivo to the active open ring form by
carboxyesterases in the liver and plasma.
B. Statins and Pleiotropic effects
The strong correlation between serum cholesterol levels and coronary artery
disease [9, 10] supported the assumption that the protective effect of statins in
cardiovascular disease is mainly attributed to the ability of statins to lower the serum
cholesterol levels. However, this notion seemed to be imprecise when subgroup
analyses of large clinical trials have suggested possible beneficial effects of statins that
may not be entirely dependent on cholesterol reduction. For instance, the risk of
myocardial infarction was found to be significantly lower in individuals treated with statins
than those treated with other cholesterol lowering agents with both groups showing
comparable reduction in serum cholesterol levels [11, 12]. Likewise, administration of
statins was associated with a substantial lower risk of developing dementia relative to
those treated with other lipid lowering agents. This effect was independent of the
presence or absence of untreated hyperlipidemia suggesting no central role of LDL
cholesterol levels in the effect of statins [13]. Moreover, the vascular protective effects of
statins were demonstrated in a clinical study where four weeks of simvastatin treatment
improved the endothelial functions in patients with heart failure compared to those
treated with ezitimibe, despite the comparable levels of LDL cholesterol in both groups
[14]. Several reports have also demonstrated the association between the use of statins
and the reduced risk of osteoporosis and multiple sclerosis [15, 16]. In a similar context,
several studies have reported the association of statins use with decreased risk of
cancer [17-19]. In a retrospective study, statins significantly reduced the risk of renal cell
carcinoma by 48% in almost half a million patients, irrespective of age, sex, smoking,
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and obesity [19]. Conversely, a recent systemic review with 42 studies failed to show
any evidence on the protective effect of statins in cancer [20]. Conclusions driven from
these studies were inconsistent which may be attributed to the nature of the studies as
being observational and retrospective [21]. Long follow up studies might be needed to
detect any potential long-latency effects of statins in cancer. Overall, these findings
strongly suggest the possible beneficial effects of statins beyond cholesterol reduction.
Thus, investigators began to unravel the molecular mechanism and the clinical
implications of these pleiotropic effects.
C. Statins and mevalonate pathway
As mentioned above, statins mediate their anti-hypercholesterolemic effect through
blocking the mevalonate pathway and subsequent decrease in cholesterol production
(Figure 1.2). Cholesterol is a vital cell membrane component and its production is
necessary for cellular membrane structure and integrity. It also acts as a precursor for
steroid hormones and bile acids synthesis [22]. However, there are several other
downstream products of the mevalonate pathway such as ubiquinone (coenzyme Q10),
dolichol and isoprenoids that were found to play a critical role in the different cell
functions. For instance, Dolichol, in the form of dolichol phosphate, plays an important
role in glycoprotein synthesis. It works as a carrier molecule of oligosaccharide in Nlinked protein glycosylation. Ubiquinone (coenzyme Q10) is involved in the electron
transport chain in mitochondrial respiration and functions as an antioxidant in the
inhibition of lipid peroxidation [23]. Isoprenoids, including geranylgeranyl pyrophosphate
(GGPP) and farnesyl pyrophosphate (FPP), are used to modify small G proteins such as
RAS and RHO GTPases that play a crucial role in cell motility, proliferation and survival
[24]. In fact, several studies demonstrated that most of the pleiotropic effects induced by
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statins including their antitumor activity are mediated through the depletion of
isoprenoids and the subsequent impairment of the small G proteins functions [25].
D. G-proteins
Guanine nucleotide-binding proteins (G proteins) are a large family of GTP binding
proteins that act as a molecular switch regulating wide variety of cell functions. There are
two main classes of G Proteins, the heterotrimeric G proteins (large G proteins) that are
composed of α, β, and γ subunits and are activated by membrane G proteins coupled
receptors. The second class is monomeric G proteins that are also known as small G
proteins or small GTPases because of its low molecular weight of 20 - 40 KDa. Small G
proteins are classified into five major families including RAS, RHO, RAB, ARF and RAN
families [26, 27].
G proteins are known to alternate between inactive GDP bound and active GTPbound states (Figure 1.3) [28, 29] . Switching between GDP and GTP binding
conformations allow these proteins to function as a molecular switch regulating several
cellular functions (Figure 1.3) [30] . Several protein classes regulate the activity of the G
proteins including; Guanine nucleotide exchange factors (GEFs) which stimulate the
dissociation of GDP from the G proteins and allow GTP binding in a passive rebinding
process; GTPase activating proteins (GAPs) which acts as negative regulators of G
proteins activity through accelerating the rate of hydrolysis of GTP to GDP [31, 32].
E. Small G proteins and Cancer
Small G proteins comprise a large class of membrane proteins with broadly diverse
functions. Recent study has indicated approximately 600 genes in the human genome
that encode proteins with C-terminal CXXX motif, a conserved recognition motif in most
of the prenylated proteins [33]. However, only more than 100 proteins have been
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identified to undergo prenylation [34]. The members of the small G protein families were
shown to play critical role in regulating several cellular responses including signal
transduction, cytoskeletal organization, and intracellular vesicle trafficking [26] . For
example, members of the RAS family are essential element in transducing signals
mediated by the extracellular microenvironment that regulate several fundamental
processes such as cell growth, proliferation and apoptosis [35-37]; the RHO family
proteins regulate signaling networks involved in cytoskeletal organization, cell cycle
progression, gene expression and cell proliferation and survival [38-41]. Both RAB and
ARF family members are involved in regulating intracellular vesicular transport and
protein trafficking between different organelles [42, 43], whereas RAN proteins are
responsible for the transport of RNA and proteins across the nuclear membrane [44, 45].
Both RAS and RHO GTPases are activated in response to signals, initiated either
extracellularly or intracellularly, that generate the active GTP-bound form and propagate
further downstream signaling events. The role of RAS and RHO GTPases in
carcinogenesis is well established [35]. Constitutive activation of RAS and RHO
GTPases, either by point mutation or over expression, will trigger downstream signaling
which are involved in cell growth and proliferation leading to uncontrolled cell growth and
proliferation and will result in tumor development [35, 38]. In 20 - 30 % of human tumors,
RAS proteins are constitutively activated by a point mutation that reduces the GTPase
activity of RAS and prevent the hydrolysis of GTP to GDP [36, 46]. The incidence of the
mutation of the RAS genes varies greatly among the different tumors, the highest rate of
mutation was found in pancreatic cancer (90%) [47], colon cancer (50%) [48, 49] and
lung cancer (30%) [50]. In addition to activation through mutation, RAS was also found
to be hyperactivated as a result of deregulated expression or by an activating mutation
of upstream signaling molecules such as growth factor receptor tyrosine kinases. The
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most common examples are EGFR and HERs that are hyperactivated in many types of
tumor such as lung, breast and ovarian cancers [51, 52]. Unlike RAS, no work has
reported activating mutations in RHO proteins; however, accumulating evidence has
shown that RHO proteins are hyperactivated in human tumors relative to normal tissue
[39].
Given the crucial role of RAS and RHO GTPases in regulating several downstream
pathways that mediate cancer growth and progression, substantial efforts were made to
target these signaling pathways in cancer therapy. Several therapeutic strategies have
been developed to inhibit these pathways through blocking the upstream signaling
molecules or inhibiting the activities of the downstream effectors [53]. One attractive
approach is to target the RAS and RHO themselves through interrupting their
posttranslational modification process, which is crucial for the proteins in order to get
anchored into the membrane and attain full activity.
F. Post translational modifications of small G proteins
It was first recognized over twenty years ago that the function of small G proteins is
dependent on a post-translational modification process that enables small G proteins
from attaching to the cellular membranes and subsequently being activated [46]. Small
G proteins are synthesized in the cytosol as hydrophilic soluble proteins that undergo a
series of modifications in order to add a lipidated hydrophobic moiety that facilitate the
anchoring of small G proteins into the lipophilic cellular membranes. These modifications
take place at the CAAX (C, cysteine; A, aliphatic amino acid; X, any amino acid) motif in
the protein carboxyl terminus at several steps including prenylation, proteolysis and
carboxymethylation (Figure 1.4). Prenylation is the first and the rate limiting step in the
modification and it includes the covalent attachment of a lipid isoprenoids moiety into the
cysteine

residue

of

the

CAAX

motif
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through

the

interaction

with

either

farnesylpyrophosphate (FPP, 15-carbon isoprenoids) or geranylgeranyl pyrophosphate
(GGPP, 20-carbon isoprenoids), which are intermediate products of the mevalonate
pathway [54]. In general, proteins carrying leucine or phenylalanine as the X residue in
the CAAX motif get geranylgeranylated and is catalyzed by geranylgeranyl transferase I
(GGTase I) enzyme, otherwise the protein gets farnesylated in the presence of farnesyl
transferase (FTase) enzyme [55]. After prenylation, Rce1 endopeptidase catalyzes the
cleavage of the three terminal amino acids (AAX) of the proteins and then the
isoprenylated

cysteine

will

get

methylated by the

isoprenylcysteine

carboxyl

methyltransferase (ICMT) [56]. N- RAS, H- RAS and K- RAS (4A) isoforms undergo
additional palmitoylation modification (addition of palmitoyl moiety) at the C-terminus
besides farnesylation, whereas K- RAS (4B) isoform attaches to the membrane through
farnesyl moiety and a polybasic, lysine rich, sequence near the terminal cysteine. These
additional modifications are also critical for the association and stability of the small G
proteins at cellular membranes. In general, these posttranslational modifications are
critical for RAS and RHO GTPases to associate with cellular membrane in order to
execute their biological functions. Given the fact that RAS and RHO GTPases play an
essential role in carcinogenesis, deactivation of these proteins through targeting their
posttranslational process is thought to be a promising strategy to fight cancer. Several
approaches were postulated to target this process either through inhibiting the rate
limiting enzymes such as FTase and GGTase (using FTase and GGTase inhibitors), or
by interfering with the mevalonate pathway (using statins), in order to inhibit the
biosynthesis of FFP and GGPP, which are critical substrates for the prenylation process.
G. Statins and antitumor activity
Although most of the epidemiological and meta-analyses reports suggest no
helpful or harmful effect of statins on cancer risk [20, 21], accumulating evidence from in-
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vitro and in-vivo studies have demonstrated the anti-tumor effects of statins in several
tumor types [57, 58]. The ability of mevalonate to abrogate the antitumor activity of
statins indicated the importance of the mevalonate pathway in mediating the antitumor
activity of statins [59, 60]. In fact, depletion of the intracellular pools of both FPP and
GGPP, as a result of the upstream inhibition of mevalonate synthesis, with consequent
dysfunction of small G proteins is suggested to be the underlying mechanism of the
antitumor activity of statins. This finding was supported by several add back studies that
demonstrated the ability of GGPP to abrogate the statin induced apoptosis in cancer
cells, whereas addition of FFP only showed partial reversal [59, 61-64]. Other products
of the mevalonate pathway including cholesterol, squalene, lanosterol, desmosterol,
dolichol, dolichol phosphate, ubiquinone and isopentenyladenine were not able to
reverse the apoptotic effect of statins in cancer cells [59, 61, 65].
Antitumor effects exhibited by statins include growth arrest, induction of apoptosis,
inhibition of angiogenesis, and repression of tumor metastases [58, 66]. Statins have
been shown to induce growth arrest at the G1/S phase in both solid tumors and
hematologic malignancies [67-72]. Many studies have shown that statins antiproliferative
effect is mediated through the induction of cyclin dependent kinase inhibitors (CKIs),
p21Waf1/Clip1 and/or p27Kip1 that downregulate the kinase activity of cyclin-dependent
kinase 2 (CDK-2), essential for G1/S transition [67, 71, 73]. Statin induced growth arrest
was shown to be rescued by the addition of mevalonate and GGPP, indicating the role of
geranylgeranylation inhibition in mediating the cytostatic effect of statins [74, 75].
Similarly, statin induced apoptosis in different tumor types has been found to be
abrogated by the addition of mevalonate and geranylgeranyl pyrophosphate (GGPP)
and was partially reversed by farnesyl pyrophosphate (FPP) [59]. The apoptotic activity
of statins is thought to be mediated through the disruption of the balance between
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proapoptotic and antiapoptotic members of the Bcl2 family, which are important
regulators of cell survival. Downregulation of antiapoptotic proteins (e.g. Bcl2 and Mcl1)
as well as increasing the expression of proapoptotic protein (e.g. Bax and Bim) was
associated with lovastatin induced apoptosis in different tumor cells [62, 76].
Furthermore, statins were found to induce apoptosis through the activation of caspase
proteases involved in programmed cell death [77, 78]. However, the molecular
mechanism by which statins generate apoptosis in tumor cells is not well defined. The
wide intracellular pool of small G proteins as well as their complicated downstream
network of signaling pathways makes it difficult to define a specific mechanism of action.
The downregulation of the Raf/MEK/ERK pathway was suggested to contribute to
lovastatin mediated apoptosis in AML cells [79]. Conversely, the apoptotic effect of
statins in both ovarian and breast cancer cells was associated with the activation of JNK
pathway and the phosphorylation of the transcriptional factor c-Jun [64, 80]. In lung
carcinoma

cells,

lovastatin

was

shown

to

inhibit

the

EGF

induced

EGFR

autophosphorylation and inhibits the AKT activation by EGF in combination with gefitinib
[81]. In addition to the in vitro antitumor activity, statins have been shown to have in vivo
antitumor activity in different animal models where simvastatin was found to have an
inhibitory effect on the proliferation of human AML cells in SCID mice [82]. Furthermore,
statins were shown to inhibit the growth of colon tumors in rats and mice [83-85] .
Building upon the evidential results obtained from both in vitro and in vivo studies
that indicate the diverse antitumor effects of statins on the different types of tumors,
clinical investigators were tempted to assess whether this antitumor activity will translate
into significant clinical benefits.
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H. Clinical trials of statins
Several clinical studies investigated the value of statins as an adjuvant treatment,
at typical doses used in the treatment of hypercholesterolemia, in improving the efficacy
of standard treatment in cancer. A randomized controlled trial in patients with advanced
hepatocellular carcinoma suggested that the addition of pravastatin, at a daily dose of 40
mg, to standard treatment prolonged the median survival to 18 months versus 9 months
in patients receiving standard treatment only [86]. Other clinical trials have shown that
the administration of simvastatin improved the efficacy of standard therapies in patients
with multiple myeloma and non-small cell lung cancer [87, 88]. Similarly, addition of
simvastatin to irinotecan, 5-fluorouracil and leucovorin (FLOFIRI) modestly prolonged
the time to progression from 6.7-8.5 months with FLOFIRI alone to 9.9 months in
patients with metastatic colorectal cancer [89]. In contradiction with previous findings,
addition of pravastatin to chemotherapy in advanced gastric carcinoma in a phase II trial
did not improve the outcome in those patients [90]. Likewise, simvastatin, at 40mg/daily,
could not improve the clinical status in chronic lymphocytic leukemia patients [91]. This
discrepancy in clinical data of statins at typical doses could be attributed to several
factors including the tumor type being treated, the limited number of patients in the
study, or the advanced stage of the disease.
Furthermore, the safety and tolerability of statins at high doses were assessed in
limited clinical trials. Lovastatin was found to be safe and well tolerated at maximum
tolerated doses 25 mg/kg/day and 35 mg/kg/day (with concomitant administration of
ubiquinone to prevent rhabdomyolysis) in cancer patients [92, 93]. In a phase I trial,
patients with myeloma or lymphoma were able to tolerate simvastatin at 7.5 mg/kg given
orally, twice daily for seven consecutive days [94]. These high doses of lovastatin and
simvastatin are more than 40 and 25 fold higher than the regular dose (40mg/day) used
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for hypercholesterolemia therapy, respectively. However, further evaluation of statins at
high doses in phase II trials showed limited efficacy in cancer patients [92, 95-97]. Based
on those negative results, it becomes important to know whether statins at high doses
are able to achieve therapeutically effective plasma concentrations. Currently, none of
the conducted clinical trials looked at the pharmacokinetics of statins at high doses.
Thus, the work contained in this dissertation characterizes the pharmacokinetics of
simvastatin given at high doses in cancer patients.
I.

Statins combined with other anticancer drugs
Given the ability of statins to inhibit the biological function of small GTPases and its

impact on several important cellular functions, numerous preclinical studies were in favor
of exploring the potential benefits of statins in combination with other anticancer
treatments. In addition, using statins in a synergistic or additive combination will give the
opportunity to utilize reduced concentrations of statins that could be achieved in the
clinic. Recently, Jakobisiak and Golab have published a review article that includes
numerous combination studies of statins with other anticancer drugs and discussed their
clinical relevance [98]. Briefly, statins have been shown to potentiate the effects of
anticancer drugs from different classes such as 5-fluorouracil, etoposide, anthracycline,
doxorubicin, cisplatin and paclitaxel [99-104]. It is interesting to note that cerivastatin
augmented the cytotoxic effect of 5- fluorouracil to a degree that only 10 -500 fold lesser
concentrations of 5- fluorouracil were required to yield similar effect of the drug alone
[101]. Likewise, synergistic interactions of statins with anticancer agents were seen at
much lower concentrations of statins relative to what have been used with statins alone
[99-104].

Moreover, statins were also shown to potentiate the antitumor activity of

several molecular targeted therapies such as celecoxib, cetuximab, sorafenib and
gefitinib [105]. In fact, fluvastatin at clinically achievable concentrations was able to
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induce synergistic interaction in combination with trastuzumab in breast cancer cells
[106]. In general, synergistic combination of statins with anticancer drugs may warrant
dose reduction of statins to clinically achievable concentrations that facilitate a smooth
transition from the in-vitro settings into clinical application. In this dissertation, a
combination of simvastatin and tipifarnib at clinically achievable concentrations was
shown to induce cytotoxic effect in leukemia cells in a synergistic fashion.
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Figure 1.1. Chemical structures of the statins.
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Glycoprotein synthesis

Cell signaling cascades
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Figure 1.2. Overview of the mevalonate pathway, its downstream products and targets for inhibition by statins,
farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors.
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Figure 1.3. A schematic of small G protein activation. Small G proteins switch between
GDP (inactive) and GTP (active) conformations which is controlled by GEF, guanine
nucleotide exchange factors and GAP, GTPase activating proteins.
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1.4.

Posttranslational

modification

of

RAS

and

RHO

GTPases.

Farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase) catalyze the
addition of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) to
the C-terminus of the small G proteins, respectively. Rce1 endopeptidase removes the
last three amino acids from the carboxyl terminus. Following the removal of the AAX
amino acids, the carboxyl terminus is then methylated by isoprenylcysteine carboxyl
methyltransferase (ICMT). Me, Methyl.
Copyright © Tamer Ahmed 2013
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Chapter 2 : Hypothesis and Specific Aims
The long term goal of our research is to evaluate the clinical utility and prospects of
simvastatin in cancer therapy. An initial objective for this dissertation work included a
phase-II clinical trial using high dose simvastatin as a therapy in patients with chronic
lymphocytic leukemia (CLL). Therefore, our studies used simvastatin as a model drug. In
efforts to develop statins into the clinic for cancer therapy, limited Phase I and II studies
have assessed the safety and efficacy of high dose statins in cancer patients. Lovastatin
has been previously studied in phase-I and phase-II studies, in solid tumors, and
simvastatin was studied in myeloma and lymphoma patients. However, the
pharmacokinetics of high dose simvastatin, although vital for its clinical development,
were not previously defined. Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors and exert their anticancer effect by inhibiting prenylation
(lipidation) of low molecular weight GTPases, such as RAS and RHO oncoproteins,
which play a key role in intracellular cancer cell signaling. In tumor cells, these signaling
pathways are deregulated and contribute to cell proliferation and inhibit apoptosis. Our
initial hypothesis was that high dose simvastatin administered for one week every 21
days for 6 cycles is safe and efficacious in adults with recurrent or refractory CLL. In
addition, we hypothesized that high dose simvastatin treatment will disrupt the cellular
localization of proteins that depend on prenylation for their trafficking and will induce
apoptosis in CLL cells.
To facilitate the planned clinical study, we first sought to determine the
pharmacokinetics of simvastatin, as well as its apoptotic effects, in a limited number
(n=3) of patients that were administered high dose at its MTD (7.5 mg/kg, twice daily, for
seven days). Therefore we conducted the studies outlined in Specific Aim 1.
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Specific aim 1: Evaluate the pharmacokinetics of high dose simvastatin in a pilot clinical
trial in (CLL) patients.
Aim 1.1: Develop, implement and validate a bioanalytical method for accurate
and precise quantitation of simvastatin lactone and simvastatin acid in plasma
and peripheral blood mononuclear cells. This work is outlined in Chapter 3.
Aim 1.2: Determine the pharmacokinetics and peripheral blood mononuclear
cells (PBMCs) biodistribution in patients treated with high dose simvastatin. This
work is outlined in Chapter 4.
Aim 1.3: Determine whether high dose simvastatin treatment induces apoptosis
in CLL cells from treated patients. This work is outlined in Chapter 4.

Based primarily on the findings from Aim 1.2, we reconsidered the use of simvastatin as
a single agent and sought to determine combination treatments that could potentially be
synergistic. In these studies we focused on combining statin with a farnesyl transferase
inhibitor (i.e., tipifarnib) which was designed to prevent lipidation (farnesylation) of RAS.
Our rationale for this combination was based on the capacity of RAS to become lipidated
by geranylgeranylation, which is a process that can be inhibited by simvastatin. Although
each drug alone can induce apoptosis, we reasoned that the combination may allow for
synergistic effects that can be achieved at lower concentrations. Our hypothesis is that
the combination of simvastatin and tipifarnib is synergistic and this synergy is conferred
by the capacity of simvastatin to block the alternative lipidation pathway of RAS, which
induces apoptosis. Therefore we conducted the studies outlined in Specific Aim 2.
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Specific aim 2: Assess the interaction between simvastatin and tipifarnib in inducing
cytotoxicity in leukemia cell lines. This work is outlined in Chapter 5.
Aim 2.1: Determine whether simvastatin synergistically induces apoptosis in
combination with tipifarnib in leukemia cells.
Aim 2.2: Determine the underlying molecular mechanisms that induce apoptosis
in simvastatin/tipifarnib treated cells including RAS membrane localization,
downstream signaling, and apoptosis.

Copyright © Tamer Ahmed 2013
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Chapter 3 : Validated LC-MS/MS method for simultaneous determination of
simvastatin and its acid form in human plasma and cell lysate: Pharmacokinetic
Application
A. Introduction
Simvastatin is a well-established drug for the treatment of hyperlipidemia.
Simvastatin is a prodrug administered in the lactone form, which is converted in the liver
into the active acid form (Figure 3.1). It is this active carboxylate form that reduces
cholesterol biosynthesis by competitively inhibiting the 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in the mevalonate pathway
[8]. Additionally, statins inhibit the synthesis of other downstream products in the
mevalonate pathway, such as the isoprenoids [8]. Isoprenoids, including farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), are known to be
involved in important cellular processes such as proliferation and apoptosis [24]. Thus,
statins have recently been tested for their potential use as anticancer agents. As with all
agents in this class, in vitro studies have shown that simvastatin displays anticancer
activity, but only at concentrations that are higher than those observed in plasma of
patients being administered typical doses associated with hyperlipidemia therapy [107].
Several clinical trials were subsequently conducted to study the safety and
tolerability of high dose statin analogues, including simvastatin, in cancer patients [9294]. Oral statins were found to be well tolerated at high doses with minor side effects. In
a phase I study, lovastatin given orally at a dose of 25 mg/kg daily was well tolerated
and safe in patients with solid tumor [93]. In the case of simvastatin, a phase I study in
patients with myeloma or lymphoma has shown that the maximal tolerated dose (MTD)
of simvastatin, given orally, is 7.5 mg/kg twice a day, which is 25-fold higher than typical
dose. The most common side effects of high dose simvastatin were nausea, diarrhea,
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muscle weakness and myalgia [94]. However, pharmacokinetics (PK) was not defined
and it is not known if simvastatin plasma concentrations can reach the levels necessary
for the antitumor activity observed in vitro. In this context, we initiated a clinical study to
characterize the pharmacokinetics of simvastatin lactone and its acid form in plasma and
peripheral blood mononuclear cells (PBMCs) after oral administration of simvastatin at
7.5 mg/kg twice daily in patients with recurrent and refractory chronic lymphocytic
leukemia (CLL).
Simvastatin has low systemic bioavailability which is attributed to the high
extraction by the liver, the main site of action for treating hyperlipidemia. Therefore,
sensitive analytical methods have previously been developed to assay both simvastatin
(SIM) and its acid form (SIMA) in plasma [109-112]. The first analytical method
developed was an LC coupled with UV detection (238 nm); nonetheless, low sensitivity
for quantitation of SIM and SIMA in biological fluids was reported [113]. Better sensitivity
using UV detection was achieved later with an LOQ of 0.5 ng/mL but with run time >
28.7 min [114]. A more sensitive HPLC-FD method using 1-bromoacetylpyrene for
derivatization has been reported with an LOQ of 0.1 ng/mL for both analytes [115].
Although this LC-FD method is highly sensitive, sample preparation using solid phase
extraction and analyte derivatization is inconvenient and time consuming. On the other
hand, several LC-MS/MS methods have been developed for the determination of SIM
and SIMA in biological fluids which are more sensitive and specific [109-112]. These
methods are coupled with either solid phase extraction (SPE) or liquid-liquid extraction
(LLE) procedures. Solid phase extraction has yielded good recoveries for SIM but SIMA
recovery was low [116]. LLE showed better recoveries for both SIM and SIMA compared
to SPE [109, 111, 112]. Current analytical methods have not been validated for the
analyses of SIM and SIMA in cell lysates. Moreover, few assays have been validated to
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measure plasma concentration of SIM and SIMA at higher levels [117-119]. Here we
report the development and validation of an LC-MS/MS method for the analysis of
simvastatin and its acid form in human plasma and PBMCs.
B. Methods
1. Chemicals and reagents
Simvastatin was purchased from Toronto Research Chemicals Inc. (North York,
Canada). Ammonium acetate (Mallinckrodt Baker, Philipsburg, NJ, USA) and sodium
hydroxide (EM Science, Gibbstown, NJ, USA) were purchased from VWR (West
Chester, PA, USA). HPLC grade acetonitrile and diethyl ether were obtained from
Sigma-Aldrich (St Louis, MO, USA). Lovastatin (Alexis Biochemicals, San Diego, CA,
USA), hydrochloric acid and glacial acetic acid were from Fisher Scientific (Fair Lawn,
NJ, USA). Anhydrous ethanol was obtained from IBI Scientific (Peosta, IA, USA). K562,
a chronic myelogenous leukemia (CML) cell line, was purchased from ATCC (Manassas,
VA, USA).
2. LC-MS/MS instrumentation and conditions
All analyses were performed using an HPLC system consisting of a Shimadzu
LC-20AD pump and a Shimadzu SIL-20AC VP auto sampler (Shimadzu, Columbia, MD,
USA). The LC system was interfaced to an API 2000 ESI-MS/MS (Applied Biosystems,
Foster City, CA, USA). The analytical column used was a Phenomenex Luna C18 (2.0
mm x 100 mm i.d.; 2.5 µm particle size), connected to a C18 guard column (Phenomenex
C18, 2.0 mm x 4 mm; 5 µm particle size). An isocratic mobile phase was used consisting
of 75:25 (% v/v) acetonitrile : ammonium acetate (0.1M, pH 5.0 adjusted with acetic
acid). The flow rate was 0.15 mL/min under ambient temperature. The auto sampler
temperature was maintained at 4°C and the injection volume was 20 µL. The run time
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was 10 min. All analytes and internal standard were detected on a triple quadrupole
mass spectrometer (API 2000), equipped with a turbo ion spray source (MDS SCIEX,
Toronto, Canada) and operating in the positive ion mode. Lovastatin (LOV) was used as
an internal standard (IS). Quantitation was performed using multiple reaction monitoring
(MRM) of precursor/product ion transitions at m/z 419.3/199.3 for SIM; 437.3/303.3 for
SIMA; and 405.2/199.3 for LOV.
The optimized source parameters for SIM, SIMA and LOV were as follows: the
nebulizer gas pressure was set at 30 psi, the heater gas at 90 psi, the ion spray voltage
was 5500 V and the turbo heater temperature was 500°C. The curtain gas pressure was
set at 40 psi and the collision activation dissociation (CAD) gas at 10 psi. Lastly the
entrance potential, declustering potential, collision energy and cell exit potential applied
were set at 8.27, 14, 17 and 5.25 V for SIM, 7, 3.8, 14 and 8.5 V for SIMA and 8.7, 12.5,
21.2 and 5.4 V for LOV, respectively. All the parameters were controlled by Analyst
software version 1.4.2 (Applied Biosystems, Foster City, CA, USA).
3. Preparation of standard and quality control samples
Stock solutions of SIM, SIMA and LOV (1 mg/mL) were prepared in ethanol.
Simvastatin acid was prepared by alkaline hydrolysis of simvastatin [120]. Standard
working solutions of SIM and SIMA were prepared by serial dilution of the appropriate
stock solutions with mobile phase. Standards were prepared fresh for each run by
spiking 25 µL of the appropriate working solutions of both analytes and internal standard
into 425 µL of drug free human plasma to obtain calibration concentrations of 2.5, 5, 10,
50, 100, 250, 500 ng/mL SIM, 5, 10, 50, 100, 250, 500 ng/mL SIMA and 50 ng/mL LOV.
Similar to plasma calibration standards, cell lysate calibration standards were prepared
at calibration concentrations of 2.5, 5, 10, 50, 80, 100, 250 ng/mL SIM, 5, 10, 50, 80,
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100, 250 ng/mL SIMA and 50 ng/mL LOV. Cell lysate matrix was prepared by lysing
K562 cells in deionized water (3 x 107 cells/mL) via sonication.
Plasma quality control (QC) sample concentrations were 7.5, 150 and 400 ng/mL
for SIM and 15, 150 and 400 ng/mL for SIMA. Cell lysate QC sample concentrations
were 7.5, 90 and 200 ng/mL for SIM and 15, 90 and 200 ng/mL for SIMA. QC samples
were prepared using stock solutions other than those used for calibration standards
preparation. Both calibration standards and QC samples were prepared at 4°C in an ice
bath.
4. Processing of plasma and cell lysate samples
All plasma and cell lysate samples were stored at -80°C and thawed at room
temperature. A 25 µL aliquot of LOV was added to 475 µL of plasma or cell lysate
sample in 16 mm x 100 mm glass test tube. The tubes then were vortexed for 10 s. After
the addition of 500 µL of ammonium acetate buffer (0.1 M, pH 5.0), tubes were vortexed
again for 1 min. Diethyl ether (3 mL) was then added to each tube and samples were
placed on a shaker at 200 rpm for 15 min at 4°C. Extracted samples were centrifuged at
3000 rpm for 10 min at 4°C. After centrifugation, the aqueous layer was frozen by
placing the tubes in dry ice for 1 min. The organic layer was decanted into a new 16 mm
x 100 mm test tube and was evaporated till dryness at room temperature using a gentle
stream of nitrogen. The residue was reconstituted in 50 µL of mobile phase and 20 µL
was injected onto the HPLC column.
5. Method validation
The method validation of SIM and SIMA in human plasma and cell lysate was
performed according to the FDA guidelines [121]. The assay was validated for specificity
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and sensitivity, linearity, precision and accuracy, extraction recovery, matrix effect, and
stability.
5.1. Specificity and sensitivity: Assay specificity and sensitivity were conducted in
eight different lots of blank plasma that was either left blank or spiked with both analytes
and IS. Analytes were extracted using the previously described extraction procedure and
analyzed to determine the extent of interference by endogenous plasma components at
the retention time of both analytes and IS. The lowest limit of quantitation (LLOQ) was
assessed in the same plasma lots used for specificity. The determination of LLOQ was
based on the criteria that the deviation of the measured concentrations should not be
more than 20% from the nominal concentration and that the signal to noise ratio be ≥ 5.
5.2. Linearity: Linearity was evaluated using plasma samples spiked with both
SIM and SIMA at concentration ranges of 2.5-500 ng/mL and 5-500 ng/mL, respectively.
The internal standard, LOV, concentration was 50 ng/mL in all calibration standards.
Three calibration curves were prepared and analyzed by plotting area ratios of analyte to
internal standard against the concentration of each calibration standard. The results
were fitted into a linear regression model using (1/y) as a weighting factor for both SIM
and SIMA. A cell lysate calibration curve was prepared similar to plasma calibration
curve, but at concentration ranges of 2.5-250 ng/mL and 5-250 ng/mL for SIM and SIMA,
respectively.
5.3. Precision and accuracy: The intra-day precision and accuracy was evaluated
at three different QC levels (low, medium and high) in eight replicates on the same day
and in five replicates on three different days for inter-day precision and accuracy
determination. Acceptable deviation was set within 15% of the nominal concentration for
accuracy and within 15% relative standard deviation for precision.
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5.4. Extraction recovery and matrix effect: The recovery efficiency of the
extraction procedure was performed at low and high QCs using the extraction procedure
described in section 2.4. Recovery was evaluated as a percentage of the peak area of
analytes that were spiked into a matrix before extraction to the peak area of analytes
that had been spiked after extraction of a blank matrix. Endogenous substances present
in biological matrix can possibly enhance or suppress analyte ionization to affect the
sensitivity, precision or accuracy of the described method. Matrix effect was assessed as
a percentage of the peak areas of control plasma extracted and then spiked with
analyte, to neat standards injected directly in the same reconstitution solvent. Matrix
effect was carried out on five different lots of blank plasma and at low and high QC
levels.
5.5. Stability: The short term and long term stability of SIM and SIMA in plasma
and cell lysate samples was evaluated under different storage conditions. All stability
experiments were performed at low and high QC levels. Both analytes were spiked
individually in order to assess the potential for interconversion between the lactone and
acid forms.
Short term stability of SIM and SIMA was evaluated in plasma and cell lysate
samples at 4°C (ice-bath) for 6 h. The autosampler storage stability was determined by
storing the reconstituted QC samples for 6 h under autosampler conditions (i.e., 4°C).
Samples were stored for a month at -80°C to evaluate long term stability of SIM and
SIMA. Lastly, the stability of SIM and SIMA in plasma and cell lysate samples was
assessed after repeated cycles of freeze and thaw (2 cycles). In each cycle the samples
were removed from -80°C storage and allowed to thaw at room temperature.
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6. Pharmacokinetic study
In a pilot clinical trial, patients received an oral dose of 7.5 mg/kg simvastatin
twice daily for one week. Only patients who signed a written consent form were enrolled
in this study. Blood samples (8 mL) were collected after the first oral dose of simvastatin
at pre-dose, 0.25, 1, 2, 3, 6, 8, and 12 hours. All samples were collected in heparinized
BD Vacutainer Cell Preparation Tubes (CPT) and immediately centrifuged (1800 x g for
30 min at room temperature) to separate plasma and PBMCs. Collected plasma and
PBMCs were stored at -80°C until analysis. At time of analysis, PBMC pellets were
thawed and lysed in 1 mL deionized water via sonication then processed as described in
section 4.
C. Results and Discussions
1. Performance of LC and MS/MS
The Phenomenex Luna C18 column, used in this study, gave a symmetric peak
shape for all analytes with an acceptable run time (10 min). Mobile phase components
were selected based on previous works where ammonium acetate was used to enhance
ionic strength of the analytes [110]. Also, different volumetric ratios of acetonitrile and
ammonium acetate buffer were tested to obtain the best peak shape for both analytes
with reasonable retention time (<10 min). In previously developed methods, simvastatin
and lovastatin (Figure 3.1) were detected in positive ion mode whereas negative ion
mode was typically favored for simvastatin acid detection [109, 110, 112]. Few studies
have utilized the positive ion mode for detecting simvastatin acid [117, 118]. However, in
our studies simvastatin acid gave better fragmentation in positive ion mode with higher
product ion signal intensities. Thus, both analytes (SIM and SIMA) and IS (LOV) were
detected in positive ion mode without the need to switch polarity during the sample run.
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MS source parameters, as well as analytes parameters, were optimized to achieve the
highest signal intensity.
2. Selectivity and sensitivity (LLOQ)
Plasma samples from eight different sources were tested for the presence of
endogenous substances that might interfere at the retention times of peaks of interest as
evaluated by chromatograms of blank plasma and cell lysate, plasma and cell lysate
spiked with SIM and SIMA at QC1 level or LOV at 50 ng/mL, plasma and PBMCs
collected from patients at predose and 12 h after receiving simvastatin at 7.5 mg/kg
twice daily (Figure 3.2). Both SIMA and SIM were well separated with retention times of
2.65 and 7.1 min, respectively. LOV was detected at 5.6 min. The chromatograms show
no interfering peaks at the retention times of both analytes and IS in the blank plasma.
However, in-source lactonization of SIMA into SIM was recognized as shown in Figure
3.2 B, where a small peak (Peak 1) can be seen on the simvastatin MRM channel (m/z
419.3/199.3) at the retention time of SIMA. A similar peak (Peak 2) occurs on the
simvastatin acid MRM channel (m/z 437.3/303.3) at the retention time of SIM, this peak
was explained as the interference of A+1 isotope from [M+NH4]+ of the simvastatin
lactone form but not by in-source hydrolysis [122]. Therefore, chromatographic
separation between SIM and SIMA is needed to eliminate the contribution of the post
column in-source lactonization and the interference of [M+NH4]+ isotope of simvastatin
lactone.
The LLOQ was tested at different levels ranging from 1-10 ng/mL and it was
found to be 2.5 ng/mL for SIM with an accuracy of 97% and 8% precision while SIMA
showed an LLOQ of 5 ng/mL with 105% accuracy and 7% precision. Previous analytical
methods have proven to be highly sensitive with a limit of quantitation ranging from 0.050.1 ng/mL [109, 110, 112, 117]. These methods developed for the determination of low
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SIM and SIMA plasma levels achieved by typical doses (40 mg). However, our method
is developed for PK study of high dose simvastatin that is 25 fold higher than typical
doses, thus LLOQ achieved was sufficient for the purpose of this study.
3. Linearity, precision and accuracy
The calibration curves of SIM (2.5-500 ng/mL) and SIMA (5-500 ng/mL) in human
plasma and SIM (2.5-250 ng/mL) and SIMA (5-250 ng/mL) in cell lysate showed
acceptable linearity. These ranges encompassed the concentrations observed in human
plasma and PBMCs collected in a pharmacokinetic study following the oral
administration of high dose simvastatin. Calibration curves (n= 3) prepared in human
plasma yielded the following regression equations y= 0.005 (±0.001) + 0.61(±0.03) x
with R2=0.997 and y= 0.002 (±0.002) + 0.23 (±0.02) x with R2=0.997 for SIM and SIMA,
respectively. Similarly, calibration curves (n= 3) prepared in cell lysate yielded the
following regression equations y= 0.003 (±0.002) + 0.65 (±0.11) x with R2=0.997 and y=
0.001 (±0.002) + 0.31 (±0.09) x with R2=0.992 for SIM and SIMA in cell lysate,
respectively.
Inter- and intra-day precision and accuracy were determined at three
concentration levels (7.5, 200 and 400 ng/mL for SIM and 15, 90 and 150 ng/mL for
SIMA). As shown in Table 3.1, inter- and intra-day precision values of SIM and SIMA,
expressed as % relative standard deviation (RSD), ranged from 1.1 to 5.3%, whereas
accuracy values ranged between 88.6 - 110.2%. The results from intra and inter-day
precision and accuracy indicate that the method reproducibility is acceptable within the
same day and on different days.
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4. Recovery and matrix effect
Analytes were extracted from biological samples using a liquid-liquid extraction
procedure; several organic solvents were tested for their extraction efficiencies such as
methyl tertiary butyl ether (MTBE), diethyl ether, ethyl acetate, acetonitrile and methanol.
Ethyl acetate showed fair recovery for SIM, but extraction efficiency for SIMA was poor.
MTBE and diethyl ether were found to have comparable extraction efficiencies for both
SIM and SIMA and were higher than those obtained by the other organic solvents used.
Although MTBE was commonly used in previous methods, diethyl ether was chosen for
LLE procedure in this study. Mean recovery values of SIM and SIMA in human plasma
were found to be 75.3% and 73.2% at QC1 level whereas at QC3 level they were 68.6%
and 58.9%, respectively. In cell lysate, mean recovery of SIM and SIMA were higher at
QC1 levels compared to plasma recovery with 95.7% and 98.1%, respectively. Recovery
values of both SIM and SIMA in cell lysate at QC3 level were similar to those in human
plasma. Furthermore, mean matrix effect values are within the acceptable range for both
SIM and SIMA, indicating that the matrix effect has no impact on the analytes
quantification. The results of the recovery and matrix effect are summarized in Table 3.2.
5. Stability
The interconversion between simvastatin and simvastatin acid is a result of
hydrolysis of SIM and lactonization of SIMA. It has been found that the interconversion
can be reduced either at low temperature or when pH is adjusted between pH 4 and pH
5 [116]. Acidified samples stored under low temperature conditions display very low
interconversion ( <1% at 4°C and 0.05% at -20°C for 4 weeks) [116]. Thus, during
method validation, the plasma and cell lysate samples were kept at 4°C at all stages of
analysis and the reconstitution solution was buffered at pH 5. As shown in Table 3.3,
simvastatin and simvastatin acid were found to be stable in human plasma, cell lysate
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and the buffered reconstitution solution for at least 6 h at 4°C. For long term stability,
both analytes were stable in human plasma and cell lysate for at least one month at 80°C (Table 3.4). Over two freeze-thaw cycles of human plasma and cell lysate, SIM
and SIMA were also found to be stable (Table 3.5).
Stability of SIM and SIMA in stock and working solutions has been tested in
several previous works. Over different solutions compositions both SIM and SIMA were
found to be stable for at least one month [109, 112, 116, 117]. However, we have tested
the stability of both SIM and SIMA in working solution kept at -80°C, and they were
found to be stable for at least one year. Lastly, no stability studies were carried out for
lovastatin as it has previously been shown to be stable under similar storage conditions
[123].
6. Pharmacokinetic study
This method was successfully applied for the determination of simvastatin and its
acid form in human plasma and PBMCs samples collected from leukemia patients
following the oral administration of high dose simvastatin. Figure 3.2 shows the MRM
chromatograms of both plasma and PBMCs samples collected from a patient 12 h after
receiving simvastatin at 7.5 mg/kg twice daily. Figure 3.3 depicts a typical
pharmacokinetic profile of SIM and SIMA in plasma and SIM in PBMCs from a CLL
patient who received high dose simvastatin. Unlike SIM, SIMA concentrations in PBMCs
were below the detection limit of the assay at all the time points of the PK study. This
could be attributed to the hydrophilicity of the carboxylate form which may limit its
accessibility to the PBMCs. Alternatively, the carboxylate may be subject to efflux by an
ATP-binding cassette transporter.
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D. Conclusions
In conclusion, an LC-MS/MS was developed and validated for the determination
of simvastatin and its acid form in human plasma and cell lysate. This assay is the first
method developed for the analysis of SIM and SIMA in cell lysate. Moreover, this assay
spans the concentration range of quantification of both SIM and SIMA that is applied for
high dose simvastatin administration. Overall, this analytical method has proved to be
successful for the analysis of SIM and SIMA in plasma and PBMCs samples collected
from a high dose simvastatin pharmacokinetic study.
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Figure 3.1. Chemical structures of (A) simvastatin, (B) simvastatin acid and (C)
lovastatin.
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Figure 3.2. Representative chromatograms of: blank plasma (A) and cell lysate (F),
plasma (B) and cell lysate (G) spiked with both SIM and SIMA at QC1 level, plasma (C)
and cell lysate (H) spiked with LOV at 50 ng/mL, patient plasma (D) and PBMCs (I)
samples collected at predose and patient plasma (E) and PBMCs (J) samples collected
12 h after oral administration of simvastatin (7.5 mg/kg).
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Table 3.1.Intra- and Inter-day precision and accuracy

Analyte

Nominal
concentration
(ng/mL)

Intra-day (n=8)
Accuracy
Precision
(mean ± SD, %)
(%RSD)

Inter-day (n=5)
Accuracy
Precision
(mean ± SD, %)
(%RSD)

Simvastatin
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QC1
7.5
110.2 (±5.7)
QC2
150
105.2 (±1.4)
QC3
400
99.6 (±2.1)
Simvastatin acid
QC1
15
95.3 (±3.0)
QC2
150
89.4 (±1.0)
QC3
400
86.8 (±2.1)
SD, standard deviation. RSD, Relative standard deviation.

5.2
1.4
2.1

96.5 (±2.5)
97.1 (±2.4)
94.7 (±2.3)

2.6
2.4
2.4

3.2
1.1
2.4

92.9 (±4.9)
90.3 (±2.3)
91.1 (±1.4)

5.3
2.5
1.5

Table 3.2. Recovery and matrix effect

Analyte

Recovery (mean ± SD, %) (n=3)
Human plasma

Cell lysate

Absolute matrix effect
(mean ± SD, %) (n=5)

75.3 (±5.8)
68.6 (±5.4)

95.7 (±4.1)
67.5 (±7.6)

98.9 (±3.3)
99.0 (±5.6)

73.2 (±4.4)
58.9 (±4.1)

98.1 (±5.8)
63.8 (±10.1)

96.4 (±3.9)
98.7 (±1.0)

Simvastatin
QC1
QC3
Simvastatin acid
QC1
QC3
SD, standard deviation.
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Table 3.3. Short term stability of the analytes in mobile phase extract, human plasma and cell lysate stored at 4°C (n=3)
Analyte concentrations at different time points (mean ± SD) a
Mobile phase extract
Human plasma
Cell lysate

Analyte

1h

3h

6h

1h

3h

6h

1h

3h

6h

QC1

99.7
(±6.7)

106.7
(±11.8)

102.7
(±10.2)

96.6
(±4.0)

99.8
(±14.4)

101.9
(±8.8)

118.9
(±11.7)

121.9
(± 21.6)

109.9
(±10.7)

QC3

100.3
(±2.4)

101.0
(±2.9)

97.9
(±2.8)

94.0
(±4.7)

113.5
(±3.0)

115.7
(±0.6)

97.1
(±12.0)

110.4
(± 11.8)

97.3
(±8.6)

QC1

101.2
(±4.6)

89.6
(±3.2)

92.8
(±3.7)

85.5
(±24.6)

94.5
(± 8.5)

102.8
(±13.5)

121.0
(±16.8)

111.9
(± 8.6)

101.1
(±9.2)

QC3

100.0
(±3.9)

98.3
(±1.8)

96.8
(±3.1)

95.0
(±10.4)

97.4
(±10.1)

97.5
(±2.9)

89.9
(±1.2)

81.4
(± 3.4)

90.3
(±3.0)

Simvastatin
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Simvastatin acid

a

Analyte concentrations are expressed as the mean percentage of time zero concentrations (± standard deviation).

Table 3.4. Long term stability in human plasma and cell lysate (n=3)
Analyte concentrations at different time points (mean ± SD) a
Analyte
1 Day

Human plasma
3 Days
1 Week 2 Weeks

QC1

105.5
(±7.6)

95.6
(±9.4)

102.5
(±10.9)

QC3

112.1
(±9.4)

97.3
(±3.6)

QC1

91.3
(±7.7)

QC3

99.1
(±7.3)

Cell lysate
1 Week 2 Weeks

4 Weeks

1 Day

4 Weeks

99.6
(±5.2)

97.0
(±6.5)

99.7
(±7.8)

90.2
(±9.2)

98.3
(±4.8)

90.5
(±5.7)

102.3
(±2.6)

101.4
(±18.3)

95.4
(±11.9)

87.4
(±4.4)

106.5
(±8.4)

99.9
(±5.2)

101.6
(±9.2)

106.1
(±13.4)

105.9
(±11.0)

106.8
(±6.5)

91.3
(±16.4)

97.1
(±5.6)

104.3
(±8.7)

104.5
(±3.2)

114.7
(±7.1)

106.5
(±3.6)

96.7
(±2.2)

106.9
(±17.3)

108.3
(±7.2)

90.4
(±14.0)

96.2
(±9.4)

83.0
(±13.2)

96.2
(±12.5)

Simvastatin
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Simvastatin acid

a

Analyte concentrations are expressed as the mean percentage of time zero concentrations (± standard deviation).

Table 3.5. Freeze and thaw stability in human plasma and cell lysate (n=3)

Analyte

Analyte concentrations at given cycle (mean ± SD) a
Human plasma
Cell lysate
1st cycle

2nd cycle

1st cycle

2nd cycle

113.9 (±11.8)
102.9 (±5.1)

103.7 (±4.7)
104.5 (±5.1)

101.5 (±10.0)
88.7 (±6.5)

95.6 (±5.1)
100.3 (±10.1)

Simvastatin
QC1
QC3
Simvastatin acid
QC1
QC3

85.4 (±4.9)
96.5 (±11.7)

95.1 (±16.5)
90.3 (±3.3)

a

91.4 (±5.3)
86.1 (±6.9)

109.9 (±6.8)
105.3 (±3.3)

Analyte concentrations are expressed as the mean percentage of time zero concentrations
(± standard deviation).
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Figure 3.3. Pharmacokinetic profiles of (A) simvastatin lactone and carboxylate in
plasma and (B) simvastatin lactone in PBMCs after oral administration of high dose
simvastatin in a CLL patient. SIM concentration in PBMCs is normalized to the protein
concentration of each PBMCs sample.

Copyright © Tamer Ahmed 2013
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Chapter 4 : Pharmacokinetics of high dose simvastatin in refractory and relapsed
chronic lymphocytic leukemia patients
A. Introduction
Over the past two decades, statins have been used safely and effectively for the
treatment of hypercholesterolemia and for lowering the incidence of cardiovascular
disease. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate
limiting enzyme at the top of the mevalonate pathway, which is responsible for
cholesterol synthesis [7, 8]. In addition to cholesterol, the mevalonate pathway yields
other downstream products such as isoprenoids, dolichol and ubiquinone [7, 8], which
are critical components for a wide range of cellular metabolic and signaling processes. In
particular, isoprenoids (farnesyl pyrophosphate and geranylgeranyl pyrophosphate) are
crucial for the anchoring of small GTPases, such as RAS and RHO family proteins, to
the cell membrane. Membrane attachment allows the subsequent activation of these
proteins, which mediate intracellular signaling for several downstream survival and
proliferation processes [24].
In this context, statins have been tested for their potential use as anticancer
agents in several tumor types. Several reports have shown that statin mediated inhibition
of isoprenoid synthesis disrupts small GTPases localization to the membrane and is
likely the underlying mechanism for the in vitro observed antitumor activity [59, 75, 79].
Notably, these reports have demonstrated that statins display anticancer activity only at
concentrations higher than those observed in plasma of patients being administered
typical doses associated with hyperlipidemia therapy [107].
Therefore, clinical investigators were prompted to study the safety and tolerability
of high dose statins in cancer patients. In a lovastatin phase-I study in patients with solid
tumors, the maximum tolerated dose of lovastatin was 25 mg/kg daily [93]. One minor
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response was also reported in a patient with recurrent high grade of glioma. In this
study, the peak plasma concentrations of lovastatin were in the range of 0.1 to 3.9 µM,
which are comparable to its IC50 values in glioma cells (0.2 - 2 µM) [124]. However, in a
subsequent phase I/II study of high dose lovastatin in patients with malignant glioma
only one partial response and one minor response were observed out of nine patients
[95]. A later phase II study, in patients with advanced gastric adenocarcinoma, tested
the effect of an even higher lovastatin dose (35 mg/kg/day), by using concomitant
administration of ubiquinone to prevent rhabdomyolysis, but the results were
negative[92]. In the case of simvastatin, a phase I study was conducted in patients with
myeloma or lymphoma and the maximum tolerated dose (MTD) of oral simvastatin was
determined to be 7.5 mg/kg twice a day, for seven days. The most common side effects
of high dose simvastatin were nausea, diarrhea, muscle weakness and myalgia [94].
However, the study design did not include pharmacokinetics and it remains unknown
whether simvastatin at high doses can reach the concentrations required for the
antitumor activity observed in vitro. In a subsequent phase II study, simvastatin at MTD
was given for 7 days followed by rapid intravenous diffusion of vincristine (0.4 mg),
adriamycin (9 mg/m2), and dexamethasone 40 mg orally (VAD) on days 7- 10. High dose
simvastatin failed to reverse clinical resistance to VAD chemotherapy in myeloma
patients [97]. Authors of this study attributed the limited efficacy of simvastatin to the
short period of treatment as well as the treatment strategy. However, failure to reach
therapeutically effective concentrations might be a possible explanation of these
unsuccessful clinical results. Here we report the pharmacokinetics of simvastatin given
at MTD in patient with recurrent and refractory chronic lymphocytic leukemia (CLL).
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B. Methods
1. Materials
Simvastatin for in vitro studies was purchased from Toronto Research Chemicals
Inc. (North York, Canada). Ammonium acetate (Mallinckrodt Baker, Philipsburg, NJ,
USA) was purchased from VWR (West Chester, PA, USA). HPLC grade acetonitrile and
diethyl ether were obtained from Sigma-Aldrich (St Louis, MO, USA). Lovastatin (Alexis
Biochemicals, San Diego, CA, USA) and glacial acetic acid were from Fisher Scientific
(Fair Lawn, NJ, USA). Heparinized BD Vacutainer Cell Preparation Tubes CPT tubes
were purchased from Becton-Dickinson (Franklin Lakes, NJ). RPMI 1640 medium,
penicillin/streptomycin, MEM vitamins and MEM non-essential amino acids were from
Life Technologies (Grand Island, NY) whereas fetal bovine serum was obtained from
Atlanta Biologicals (Lawrenceville, GA).
2. Study Design and subjects
Eligible subjects were at least 18 years old and diagnosed with CLL utilizing
WHO classification criteria [125]. All patients had previously received treatment and
either had refractory or relapsed CLL. At the time of treatment subjects had either
disease-related symptoms or progressive disease with deterioration of blood counts,
discomfort from lymphadenopathy or hepatosplenomegaly, recurrent infections, or
associated autoimmune disorders that necessitated further therapy.

Patients were

required to have a normal serum bilirubin level and serum transaminase levels of no
more than 50% above the upper limit of institutional normal limits. All patients provided
written informed consent for this study, which was approved by the institutional review
board of the University of Kentucky (Lexington, KY).
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Simvastatin was administered orally twice daily for seven consecutive days at a
dose of 7.5 mg/kg per dose. All doses were administered using 80 mg tablets and were
rounded to the nearest 80 mg increment. A 14-day washout followed the seven days of
treatment comprising a 21-day treatment cycle. Patients were evaluated for progression
and unexpected toxicities prior to commencing with each treatment cycle and were to be
treated for 6 cycles. All grade 3 or 4 adverse events, except for nausea or diarrhea that
resolved to less than grade 1 with appropriate anti-emetics or anti-diarrhea medications
required a treatment reduction. Additionally, any patient experiencing grade II muscle
weakness or grade II creatine phosphokinase (CPK) elevation required a dose
reduction.
During study treatment, patients underwent weekly or bi-weekly evaluations that
included history, physical examination, complete blood counts and comprehensive
chemistry profiles. Toxicities were graded according to the National Cancer Institute
Common Toxicity Criteria (version 3.0). The NCI CLL revised guidelines for diagnosis
and treatment were utilized to determine the level of clinical response [126]. The clinical
trial was registered with clinicaltrials.gov, NCT00828282, prior to enrolling patients and
was conducted in compliance with the principles of the Declaration of Helsinki.
3. Pharmacokinetic study design
Serial blood samples (8 mL) were collected in heparinized BD Vacutainer Cell
Preparation Tubes (CPT) tubes during cycle 1 at predose, 15 min and 1, 2, 3, 6, 8, 12,
and 24 hours and at predose on day 7. Upon collection, samples were immediately
centrifuged (1800 x g for 30 min at room temperature) to separate plasma and peripheral
blood mononuclear cells (PBMCs) from whole blood. Top layer (plasma and PBMCs)
was collected and centrifuged at 1500 rpm for 5 min to separate plasma from PBMCs
and samples were stored at -80°C until analysis.
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4. LC-MS/MS Analysis
An LC-MS/MS method was developed and validated to measure simvastatin and
its acid form in plasma and PBMCs obtained from CLL patients enrolled in this pilot trial
[127]. Briefly, all analyses were performed using an HPLC system consisting of a
Shimadzu LC-20AD pump and a Shimadzu SIL-20AC VP auto sampler (Shimadzu,
Columbia, MD, USA). The LC system was interfaced to an API 2000 ESI-MS/MS
(Applied Biosystems, Foster City, CA, USA). Chromatographic analyte separation was
carried out on a reverse-phase Phenomenex Luna C18 column (2.0 x 100 mm i.d.; 2.5
µm particle size), connected to a C18 guard column (Phenomenex C18, 2.0 x 4 mm). An
isocratic mobile phase was used consisting of 75:25 (% v/v) acetonitrile: ammonium
acetate (0.1M, pH 5.0 adjusted with acetic acid). The flow rate was 0.15 mL/min under
ambient temperature. The autosampler temperature was maintained at 4°C and the
injection volume was 20 µL. The run time was 10 min. All analytes and internal standard
were detected on a triple quadrupole mass spectrometer, equipped with a turbo ion
spray source and operating in the positive ion mode. Lovastatin was used as an internal
standard. Quantitation was performed using multiple reaction monitoring (MRM) of
precursor/product ion transitions at m/z 419.3/199.3 for simvastatin lactone; 437.3/303.3
for simvastatin carboxylate; and 405.2/199.3 for lovastatin. All the parameters were
controlled by Analyst software version 1.4.2 (Applied Biosystems, Foster City, CA, USA).
For analysis, plasma and PBMC pellets were thawed and PBMC pellets were
lysed in 1 mL deionized water via sonication. A 25 µL aliquot of lovastatin (2.5 µM) was
added to 475 µL of plasma or cell lysate sample in 16 x 100 mm glass test tube. The
tubes then were vortexed for 10 s. After the addition of 500 µL of ammonium acetate
buffer (0.1 M, pH 5.0), tubes were vortexed again for 1 min. Diethyl ether (3 mL) was
then added to each tube and samples were placed on a shaker at 200 rpm for 15 min at
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4°C. Extracted samples were centrifuged at 3000 rpm for 10 min at 4°C. After
centrifugation, the aqueous layer was frozen by placing the tubes in dry ice for a minute.
The organic layer was decanted into a new 16 x 100 mm test tube and was evaporated
till dryness at room temperature using a gentle stream of nitrogen. The residue was
reconstituted in 50 µL of mobile phase and 20 µL was injected onto the HPLC column.
5. Pharmacokinetic data analysis
Plasma concentrations versus time data were evaluated by compartmental
modeling using Phoenix WinNonlin 6.2 (Pharsight Corporation, Mountain View, CA).
Various compartment models were tested to determine the most appropriate model. The
plasma pharmacokinetic parameters of simvastatin lactone and carboxylate, including
the maximum observed plasma concentration (Cmax) and time to Cmax (Tmax), terminal
phase elimination half-life (t1/2) and the area under the plasma concentration-time curve
(AUC) from time 0 to time of the last measurable concentration (AUCt) were also
calculated by non-compartmental analysis. PBMCs concentration of simvastatin was
calculated based on the cellular volume of the collected PBMCs sample with considering
the volume of CLL cell = 200 fL [128]. CLL cell count in each sample was determined
through measuring the protein concentration of the sample relative to those obtained
from standard CLL samples with known cell count.
6. Specimen collection and CLL cell isolation from PBMCs
All samples were processed as described above. A portion of the separated
PBMC pellets was resuspended in FACS buffer (phosphate-buffered saline (PBS), pH
7.2, 0.5% bovine serum albumin (BSA), and 2 mM EDTA) at concentration of 2 million
cells/mL. Cells were stained with anti-CD5-PE (2.5 µL) and anti-CD19-FITC (2.5 µL)
antibodies (Becton-Dickinson, Franklin Lakes, NJ) per 250 µL of suspended cells
(500,000 cells) in polystyrene tubes. Samples were mixed and incubated for 30 minutes
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in the dark at 4°C. After incubation cells were washed twice with 1 mL FACS buffer,
resuspended in 300 µL of buffer and then analyzed using FACScan flow cytometer
(Becton Dickinson, Franklin Lakes, NJ). CLL cells in PBMC samples were both CD5 and
CD19 positive. If staining was ≥ 85% in the PBMC (i.e., CLL cells represent ≥ 85% of
PBMCs), the sample was used without any further separation. Otherwise, CLL cells
were isolated using CD19 microbeads (Miltenyi Biotec, Auburn, CA).
Briefly, a 20 µL aliquot of CD19 magnetic microbeads was added to 80 µL FACS
buffer containing 1 x 107 cells. Samples were mixed and incubated for 15 min at 4°C.
Cells were washed using 1 mL FACS buffer, centrifuged at 300 x g for 10 min, and
resuspended in 500 µL of buffer. A MACS LS column was used to separate CD19
labeled cells. After applying the cell suspension, the column was washed with buffer to
elute unlabeled cells. CD19 magnetic microbead labeled cells were then flushed out
from the column by firmly pushing the plunger into the column. The collected CLL cell
sample was again stained with CD5/CD19 to ensure that the CLL cells were enriched to
85% or more.
7. Western blotting
A portion of the isolated cells collected from CLL patients at pre-dose on day 1
and day 7 of cycle 1 were washed twice with ice cold PBS buffer. Cell pellets were lysed
in RIPA buffer (50 mM Tris, pH8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
1 mM EDTA, 0.1% SDS) supplemented with Complete® protease inhibitor cocktail
(Roche Diagnostics, Indianapolis, IN) and incubated for 30 min (4°C) on a rotating
shaker. Cell lysates were then centrifuged at 1500 rpm for 5 min to remove any
particulates. Protein concentrations were measured using the BCA protein assay
(Thermo Scientific, Rockford, IL). Samples were boiled at 95°C for 10 min with NuPage
LDS sample buffer (Invitrogen, Eugene, OR) and 0.1 M DTT (Sigma, St. Louis, MO).
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Proteins electrophoresis was performed on 10% SDS-polyacrylamide gel (SDS-PAGE)
at room temperature and proteins were transferred to a polyvinylidene fluoride (PVDF)
membrane (Millipore, Billerica, MA) at 4°C. Membranes were blocked for 2 hr at room
temperature with tris-buffered saline (TBST) or phosphate-buffered saline (PBST)
containing 0.05% (v/v) Tween-20 and supplemented with 5% (w/v) nonfat milk or BSA.
Membranes were incubated overnight at 4°C with the following primary antibodies at
1:1000 dilution: anti-cleaved PARP, Bcl2, phospho ERK, ERK, phospho p38, p38,
phospho JNK, JNK and GAPDH rabbit polyclonal antibodies (Cell Signaling Technology
Inc.). After washing with TBST or PBST, the membranes were probed with HRPconjugated secondary antibody for 1 hr at room temperature. Following washes with
TBST or PBST protein bands were visualized by enhanced ECL (Thermo Fisher
Scientific, Rockford, IL) using the Kodak Image Station 2000 MM (Eastman Kodak,
Rochester, NY).
8. Cell Culture of immortalized cell lines and primary CLL cells
Primary cultures were derived from the peripheral blood of the CLL patients
(other than those involved in the clinical trial) with informed consent before therapy. CLL
cells were isolated from PBMCs as described above. CLL cells were maintained in RPMI
1640 medium (supplemented with 20% FBS, 1% MEM non-essential amino acids, 1%
MEM vitamins and penicillin/streptomycin) [129] and were allowed to recover for 24 hr
before use in the designed experiments. All cultures were maintained at 37°C in a
humidified atmosphere of 5% CO2 and 95% air.
9. Cell viability assay
Primary CLL cells were plated in 96 well plates at a density of 5 x 105 cells per
well in 100 µL of medium. Cells were incubated with increasing concentrations of
simvastatin (0 - 200 µM) for 48 hr at 37°C. At the end of the incubation period, 20 μL of
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MTS reagent (Promega Corporation, Madison, WI) was added to each well and further
incubated for 4 hr at 37°C. Cell viability was determined by measuring the absorbance at
490 nm wavelength using Molecular Devices Spectramax M5 plate reader.
10. Apoptotic assay
Primary CLL cells (5 x 106 cells/mL) were incubated in a 6 well plate with different
concentrations of simvastatin (0, 10, 50 and 100 µM) for 48 hr at 37°C. After incubation,
cells were harvested and washed twice with ice cold PBS buffer. The cell pellet was
resuspended in Annexin binding buffer (50 mM HEPES, 700 mM NaCl, 12.5 mM CaCl2,
pH 7.4) at a concentration of 1 x 106 cells/mL. To identify dead and apoptotic cells, 1 µL
propidium iodide (PI) and 5 µL Annexin V-FITC (Invitrogen, Eugene, OR) were added to
each 100 µL of cell suspension and samples were incubated for 15 min at room
temperature. Samples were diluted to 500 µL using annexin binding buffer before
analysis using FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Cells
that were positive for Annexin-V but negative for PI were those in early stage apoptosis
while cells positive for both annexin-V and PI were in late stage apoptosis.
11. Statistical analysis
Data are reported as mean values ± SD and analyzed statistically with one-way
ANOVA followed by Turkey’s post-hoc test. P values ≤ 0.05 were considered significant.
C. Results
1. Plasma and PBMCs pharmacokinetics
Three patients were accrued between July 2009 – January 2011.

The first

participant accrued, remained on treatment for three cycles of therapy before
experiencing disease progression. Of note, this participant reported an initial decrease
in constitutional symptoms including fatigue and the clinical investigators noted a
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substantial decrease in the patient’s palpable adenopathy.

Due to the waxing and

waning nature of CLL, it is unknown if the change in symptoms and adenopathy is
attributable to the effect of simvastatin. The subsequent two participants experienced
progression of leukemia during their first cycle of therapy and were subsequently
removed from therapy.

One participant experienced grade 1 limb pain as the only

toxicity attributed to the treatment.
Simvastatin lactone and carboxylate analyses in plasma and PBMC samples
were performed using a validated LC/MS/MS assay. Figure 4.1 illustrates the
chromatograms of simvastatin lactone and carboxylate in plasma and PBMC collected
from one patient, 1 hr after oral administration of high dose simvastatin.
As shown in Figure 4.2, simvastatin lactone was more predominant than
carboxylate in plasma. Non-compartmental analysis using the concentrations from
Figure 4.2 was initially used to determine the AUC, Cmax, Tmax, and terminal half-life of
each simvastatin form in these patients and values are summarized in Table 4.1. As
expected by the low number of patients and the magnitude of the oral dose, we
observed high interpatient variability in all parameters for both simvastatin lactone and
carboxylate. Conversely, several structural models were fitted to the plasma data
obtained from the three CLL patients. In contrast to a previous population study [130],
two compartment structural model representing only the central compartments of lactone
and carboxylate did not adequately fit the data of both the second and third patients.
However, a four compartment model was found to best describe the data and the
distribution phase of both forms to the peripheral compartment, as depicted in Figure
4.2. To minimize the number of parameters to be estimated by the model some
assumptions were made. Based on the previous simvastatin pharmacokinetic studies
[130, 131], we assumed the interconversion clearance (CL12) of simvastatin lactone to
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carboxylate to be 40% of the elimination clearance (CL10/F) of the lactone form.
Furthermore, we considered the reconversion of carboxylate to the lactone form as
being negligible [131]. Also, both clearances from and to peripheral compartments of
simvastatin lactone and carboxylate were assumed to be equal (CL13=CL31 ≠ CL24=CL42,
respectively) and were fixed. Lastly, fixing the absorption rate constant (Ka) at 2.76 1/hr
[130] as well as the peripheral volume of distribution of simvastatin lactone (V3) or
carboxylate (V4) was found to improve the fit and the accuracy of the estimated
parameters. Figure 4.2a and b show the plasma concentration versus time profile of both
simvastatin lactone and carboxylate after oral administration of simvastatin at 7.5 mg/kg
to the three CLL patients.
As shown in Figure 4.2, patient 2 had higher plasma concentrations of both forms
of simvastatin relative to the other two patients. Simulation of multiple dosing of
simvastatin based upon the final PK model for 6 days revealed no accumulation of either
simvastatin lactone or carboxylate after the second dose or at day 6 in the three patients
(Figure 4.2). The model predicted clearance also showed that there was a 5-fold
variation in the estimated lactone clearance (i.e., CL/F) (Table 4.1).
Similarly, simvastatin lactone and carboxylate was measured in PBMCs and as
shown in Figure 4.3, patient 2 had the highest concentrations, as compared to the other
patients, which correlated with their plasma concentrations (R2= 0.9715, Figure 4.4).
Notably, it was only the simvastatin lactone that was detectable in the PBMC of these
three patients.
2. In vivo antitumor activity of simvastatin in CLL patients
Although simvastatin at high dose showed limited efficacy in all three patients,
molecular analyses showed that simvastatin had an effect. Upon treatment with high
dose simvastatin for 7 consecutive days, CLL cells collected from patient 1 and 2
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showed elevated level of cleaved PARP (apoptotic marker) expression compared to day1 predose sample (Figure 4.5). In fact, the Bcl2 protein is often highly expressed in CLL
cells and is thought to slow the apoptosis process which leads to their accumulation in
peripheral blood [132, 133]. Moreover, the MAPK pathways were shown to be important
regulators of CLL survival [134-137]. Therefore, we examined the effect of simvastatin
on the expression of Bcl2 as well as MAPKs (p38, JNK and ERK) in CLL cells collected
from the three treated patients. As shown in Figure 4.5, simvastatin treatment does not
seem to affect the expression of Bcl2 protein or any of the MAPK family members in the
second and third CLL patients. Of note, the first CLL patient showed elevated expression
of both basal and phosphorylated MAPKs after treatment with simvastatin.
3. In vitro antitumor activity of simvastatin in primary CLL cells
The anti-proliferative activity of simvastatin was also assessed in primary cells
collected from CLL patients using the MTS colorimetric assay. This assay relies on the
ability of viable cells to actively metabolize the MTS tetrazolium salt into its formazan
product that has an absorbance measured at 490 nm wavelength. A dose dependent
decrease in cell viability of primary CLL cells was observed upon continuous simvastatin
(0-200μM) treatment for 48 hours (Figure 4.6a). The IC50 values ranged from 47.98112.6 µM (Mean ± SD, 94.4 ± 26.6 µM). We next assessed the ability of simvastatin to
induce apoptosis in primary CLL cells collected from three patients. Similarly, primary
CLL cells were exposed to increasing doses of simvastatin (0-200 µM) for 48 hours and
cells were stained with Annexin V and PI. Staining demonstrated a statistically significant
increase in the percentage of cell apoptosis when treated at 100 µM simvastatin for 48
hr relative to control (Figure 4.6b).
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D. Discussion
Beyond their cholesterol lowering effect, several reports have shown that statins
have anticancer properties in different tumor types [57, 66]. This effect is believed to be
mediated through the inhibition of isoprenoid synthesis and the subsequent deactivation
of small GTPases, which are involved in regulating multiple cellular functions including
proliferation and survival [75, 79]. However, these in vitro studies have shown that
statins display their anticancer activity at micro molar concentrations that cannot be
achieved with typical anti cholesterolemia doses [107]. This provided the rationale for
testing the safety and tolerability of statins at high doses in cancer patients. Simvastatin
was well tolerated and its MTD was 7.5 mg/kg twice daily for 7 consecutive days in a 21day cycle. This pilot clinical study demonstrated that simvastatin administered at its MTD
achieved low micro-molar concentrations (Cmax), which based on in vitro evidence, are
unlikely to be effective.
Initial attempts to fit the pharmacokinetic data to a two-compartment model, as
previously reported, were not successful in two of three patients. A four compartment
model was found to better characterize the data obtained from these patients. However,
in order for the model to fit the data, several assumptions, based on previous
pharmacokinetic publications, had to be made. Furthermore, although the model was
adequately fit to data from day 1, it did not predict the modest accumulation of either
form of simvastatin, which was observed on day 7. This observed accumulation maybe
due to slight saturation of metabolic and/or transport processes following the repetitive
administration of high dose simvastatin.
Our results are in accord with previous studies of high dose lovastatin. In that
study, patients with solid tumors were administered lovastatin and the MTD was 25
mg/kg [93]. As a part of the study pharmacokinetics were conducted and peak plasma
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concentrations ranged from 0.1-3.9 µM with an average concentration 2.32 µM. These in
vivo concentrations were found to be comparable to those effective in glioma cells in
vitro. Nonetheless, this approach did not show success in the clinic where high dose
lovastatin exhibited limited efficacy in glioma patients in a subsequent phase II trial [95].
Although lovastatin is known to cross blood brain barrier [138], it is not known whether it
can reach the brain at similar concentrations as those achieved in plasma. Similarly,
simvastatin at its MTD (7.5 mg/kg, given orally, twice a day) failed to reverse clinical
resistance to VAD chemotherapy (vincristine 0.4 mg, adriamycin 9 mg/m2, and
dexamethasone 40 mg) in myeloma patients [97]. The short period of treatment (7 days)
as well as the treatment strategy was denoted as potential factors that contributed to the
unsuccessful clinical results. However, a longer period of treatment (21 days) with
lovastatin at 7.5 mg/kg/day did not show any objective responses in patients with head
and neck squamous cell carcinoma or cervical cancer [139]. Recently, a phase II study
found no evidence of beneficial effect of high dose simvastatin on disease markers in
multiple myeloma patients [96]. The investigators of those two clinical studies of high
dose simvastatin assumed that simvastatin reaches similar concentrations in plasma to
those achieved with lovastatin. This was a reasonable assumption, since the
pharmacokinetics of these two statins is similar at lower doses [140] . Although few
patients were accrued in our study, results from the plasma analysis of simvastatin after
high dose have proven this assumption. The simvastatin plasma concentrations in our
patients showed similar but relatively lower Cmax concentrations (0.08 - 2.2 µM)
compared to lovastatin (Cmax: 0.1 – 3.9 µM). This higher Cmax range of lovastatin is likely
within the interpatient variability range and may also be attributed to the difference in
dosage regimen. Lovastatin dosing was more frequent (6.25 mg/kg four times daily)
relative to simvastatin (7.5 mg/kg twice a day). Overall, our study was in agreement with
previous lovastatin studies that reported low micro molar concentrations in plasma after
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administering high doses [93, 141]. Moreover, the high interpatient variability seen in
these studies was also observed among patients enrolled in our study which may be
attributed to several factors including, differences in metabolism, as well as differences
in oral absorption, due to efflux or incomplete dissolution of the high doses administered
[142].
The few aforementioned Phase II trials of high dose statins were initiated
considering the fact that plasma peak concentrations achieved by these doses have
been shown to be effective in vitro. However, the limited activity of statin seen in these
clinical trials addresses some concerns about whether statins at high doses are really
achieving therapeutically effective concentrations at the relevant tissues. Several in vitro
studies have reported that statins were effective against glioma and myeloma cells at
low micro-molar concentration ranges 1–10 µM [143-146] and 0.8–13.3 µM [62, 147,
148], respectively. Noteworthy is the fact that the primary cells collected from glioma and
myeloma patients were found to be more resistant to statins compared to established
cell lines. For example, lovastatin were found to inhibit the proliferation of primary cells
obtained from myeloma patients at 10- 100 µM [149]. Similarly, lovastatin inhibited cell
proliferation of primary glioma cells at IC50 values ranging from 6 – 63 µM [148], while it
was shown to induce 10 – 30 % apoptosis in primary cells at 10 µM [150]. Together,
these observations indicate that the maximum plasma concentrations achieved with high
dose statins are only approaching the lower range of effective concentrations required
for anticancer activity in primary myeloma and glioma cells. Therefore, comparing
effective in-vitro concentrations of statins in established cancer cells with those seen in
patients may not be a valid approach in these cases. In agreement with this observation,
our in vitro data indicate that simvastatin induces apoptosis in primary CLL cells only at
suprapharmacologic concentrations (~100 µM), which are not attainable in vivo. This
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may in part explain the progression of leukemia in the CLL patients treated with high
dose simvastatin in this study.
From another perspective, simvastatin carboxylate is known to be the active form
that mediates the antitumor activity of simvastatin through the inhibition of the HMG-CoA
reductase enzyme. In our study, simvastatin carboxylate was found to be present in
plasma at lower concentrations compared to simvastatin lactone. Moreover, it was not
observed (or below the detection limit 5 ng/mL (0.01 µM)) in CLL cells isolated from
these patients, even at high level of exposure as in second CLL patient. The hydrophilic
nature of the carboxylate form may have hindered its accessibility into CLL cells. In
general, limited accessibility of the simvastatin active form to the tumor site may be
considered a critical factor added to other factors that contribute to the poor response
seen in all the previous clinical trials. Despite the limited efficacy shown in all the CLL
patients, CLL cells collected form two patients after treatment with simvastatin were
shown to undergo apoptosis. However, this apoptotic effect was independent of the
survival pathways of CLL cells, such as MAPK pathways or Bcl2 protein, which were not
affected by treatment. Interestingly, there was no correlation between level of exposure
to simvastatin in CLL patients and the molecular apoptotic effect of simvastatin on CLL
cells isolated from these patients.
E. Conclusion
In conclusion, pharmacokinetic data in CLL patients showed that simvastatin
administered at its MTD achieves plasma concentrations that are far lower than those
shown to be effective ex vivo in primary CLL cells. In view of these data, the use of
simvastatin as a sole therapy for treatment of CLL, and perhaps other cancer types, is
unlikely to be successful. However, rational combination therapy that includes statins
may still provide clinical benefit.
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Table 4.1. Pharmacokinetic parameters in plasma for simvastatin lactone and carboxylate after oral administration of MTD of
simvastatin to CLL patients (n=3).

PK Parameters

Simvastatin lactone*

Simvastatin carboxylate

Patient #1

Patient #2

Patient #3

Average (SD)

Patient #1

Patient #2

Patient #3

Average (SD)

t1/2 (hr)

3.7

3.5

2.1

3.1 (0.8)

3.7

4.1

4.8

4.2 (0.5)

Cmax (µM)

0.08

2.2

0.42

0.9 (1.1)

0.03

0.6

0.13

0.25 (0.3)

AUC12 (µM*hr)

0.42

4

1.46

1.9 (1.8)

0.25

1.3

0.93

0.8 (0.5)

1

1

2

1.3 (0.5)

6

1

3

3.3 (2.5)

CL/F (L/hr)

1811

375

606

927 (774)

963

440

281

567 (354)

V/F (L)

12968

292

2046

5102 (6868)

3919

145

15

1363 (2214)

Tmax (hr)
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t1/2: terminal half-life; Cmax: maximum concentration; AUC12: area under the concentration versus time curve for 12 hours; CL: clearance and V:
volume of distribution; F: bioavailability.

Figure 4.1. Representative chromatograms of patient plasma (a) and PBMCs (b)
samples collected 1 hr after oral administration of simvastatin (7.5 mg/kg). SIM,
simvastatin lactone and SIMA, simvastatin carboxylate.
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Figure 4.2. Simulated plasma concentration versus time profiles in CLL patients (n=3)
after oral administration of simvastatin at MTD regimen (7.5 mg/kg/twice a day), (a)
simvastatin lactone, SIM (b) simvastatin carboxylate, SIMA. The solid lines represent
simulated estimated concentrations which were generated using Phoenix WinNonlin 6.2,
(c) Schematic representation of the final four compartment PK model with first order oral
absorption.
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Figure 4.3. PBMCs concentration-time profile of simvastatin lactone following oral
administration of MTD simvastatin in CLL patients. Simvastatin concentrations were
normalized to the cellular volume of CLL cells in each PBMCs sample. SIM, simvastatin
lactone. CLL cell volume = 200 fL [128].
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Figure 4.4. Association of Cmax concentrations of simvastatin lactone in plasma and
PBMCs of CLL patients.
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Figure 4.5. Effect of high dose simvastatin on the expression level of MAPK and Bcl-2
proteins (a) and cleaved PARP protein (b) in CLL cells isolated from patients before and
after therapy with 15 mg/kg/day simvastatin for 7 consecutive days. CLL cells were
isolated from treated patients and sorted by FACS (CD5+/CD19+). Cells were processed
for western blot analysis to assess the expression of JNK, phospho JNK, ERK, phospho
ERK, p38, phospho p38, Bcl-2 and c-PARP proteins. GAPDH, a cytosol protein, was
used as a loading control.
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Figure 4.6. Treatment of CLL patient cells with simvastatin reduces cell viability (a) and
induces apoptosis (b). CLL cells were freshly isolated from patients and sorted by FACS
(CD5+/CD19+). CLL cells were treated for 48 hr with increasing concentrations of
simvastatin (0-200µM). The percentage of viable cells was measured using MTS assay.
Apoptosis was measured using Annexin V/PROPIDIUM IODIDE assay and results
represent percentage of apoptosis (early and late). Data are presented as mean ± SD. *
P ≤ 0.05.

Copyright © Tamer Ahmed 2013
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Chapter 5 : Simvastatin interacts synergistically with tipifarnib to induce
apoptosis in human leukemia cells through the disruption of RAS membrane
localization and interruption of ERK pathway
A. Introduction
The RAS/MEK/ERK signaling pathway encompasses several proteins that play
key roles in cell proliferation as well as in the prevention of apoptosis of leukemic cells
[151]. Aberrant regulation of this pathway is observed in leukemia because of RAS
mutations, which lead to its constitutive activation, as well as genetic alteration of
upstream signaling molecules of the RAS [152, 153]. Pharmacologic intervention to
attenuate this pathway is thus a potential therapeutic strategy for leukemia treatment.
However, it has been difficult to identify molecules that directly inhibit the function of
RAS, and alternative approaches to prevent or block the membrane localization of RAS
have been tried as a way to pharmacologically limit the activation of this pathway [24,
154].
RAS is a small GTP-binding protein that functions as a molecular switch
regulating several signaling pathways that play a crucial role in controlling the activity of
cell proliferation, differentiation and malignant transformation [30, 35-37]. RAS activation
requires a series of posttranslational modifications to allow its association with the inner
face of the cell membrane, where it can interact with membrane receptors and activate
downstream signaling cascades [24]. The first and most crucial step in RAS
posttranslational modification is the covalent attachment of the farnesyl moiety into RAS
carboxyl terminal in a process called farnesylation and is catalyzed by the
farnesyltransferase (FTase) enzyme [24].
FTase inhibition was proposed as a strategy to impede RAS localization to the
membrane and its subsequent activation. Therefore, several farnesyltransferase
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inhibitors (FTIs) were developed and evaluated in preclinical and clinical settings against
a variety of human cancers. The preclinical evaluation of FTIs in cell culture and animal
models has shown promising results as potential therapeutic agents and several FTIs
progressed into clinical trials [155]. However, the efficacy of FTIs as a single agent in
patients with solid tumors was limited, but some modest efficacy was observed in
hematologic malignances [156, 157]. Resistance to FTIs has been attributed to
posttranslational modification of RAS by an alternative lipidation pathway, whereby RAS
can be geranylgeranylated by geranylgeranyltransferase I (GGTase I) in the presence of
FTIs [158]. This alternative isoprenylation mechanism enables RAS to associate with the
cell membrane and retain full biologic activity despite of the blockage of the farnesylation
pathway.
Understanding the mechanism by which RAS escapes the effect of FTIs tempted
the investigators to change their strategy by targeting both prenylation pathways in order
to avoid the cross-geranylgeranylation of RAS and knockdown its activity. Therefore,
considerable effort has been made to evaluate the FTIs with geranylgeranyltransferase
inhibitors (GGTI) in combination. Although several studies have demonstrated
synergistic cytotoxicity and apoptotic activity of FTI/GGTI combinations in different tumor
types, significant toxicity was reported in preclinical models, which is mostly related to
GGTI, thereby limiting the therapeutic potential of this combination [159, 160]. Recently,
GGTI-2418, a novel geranylgeranyltransferase inhibitor, was found to be well tolerated
with minimal side-effects in a phase I trial in patients with refractory solid tumors [161].
Simvastatin , an anti-hyperlipidemic drug that inhibits 3-hydroxy 3-methylglutaryl
coenzyme A (HMG-CoA) reductase, has been shown in several studies to induce
apoptosis in cancer cells through blockade of the geranylgeranylation pathway of small
GTPases [59, 75, 79]. Unlike GGTIs, statins are known to be well tolerated and have a
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wide margin of safety. Given the ability of simvastatin to inhibit the alternative pathway of
RAS prenylation as well as its good safety profile, we postulated that simvastatin could
overcome tipifarnib resistance and augment its antitumor activity in leukemia cells.
B. Methods
1. Chemicals
Simvastatin was purchased from Toronto Research Chemicals Inc. (North York,
Canada). Tipifarnib was purchased from Selleck Chemicals LLC, Houston, TX, USA.
Absolute ethanol was obtained from Sigma-Aldrich (St Louis, MO, USA). RPMI-1640
medium and penicillin/streptomycin were from Life Technologies (Grand Island, NY,
USA), whereas fetal bovine serum (FBS) was obtained from Atlanta Biologicals
(Lawrenceville, GA, USA). Alexa Fluor® 488 annexin V/Dead Cell Apoptosis Kit and
NuPage LDS sample buffer were from Invitrogen (Eugene, OR). Antibodies were
purchased

from

Cell

Signaling

(Danvers,

MA

,USA).

Mevalonate,

farnesyl

pyrophosphate and geranylgeranyl pyrophosphate were from Sigma-Aldrich (St Louis,
MO, USA). Propidium iodide was obtained from (Invitrogen Corporation, Carlsbad, CA).
Riponuclease A from bovine pancreas, resazurin and dithiothreitol (DTT) were
purchased from Sigma-Aldrich (St Louis, MO, USA). BCA protein assay was from
Thermo Scientific, Rockford, IL, whereas Complete protease inhibitor cocktail was
obtained from Roche Diagnostics, Indianapolis, IN.
2. Cell culture and treatment
All cell lines (KG1 and HL60 acute myelogenous leukemia; K562, chronic
myelogenous leukemia; Molt4, Jurkat and HSB2, acute T cell leukemia) were purchased
from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium
supplemented with FBS, penicillin (100 IU/mL) and streptomycin (100 µg/mL) at 37°C in
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a humidified incubator with 5% CO2. FBS was added to medium as follows: 20 % for
KG1 and HL60 cells, 10 % for Jurkat, Molt4 and HSB2 cells or 5% for K562 cells.
Cells were suspended in growth medium at 5 x 105 cells/mL for KG1, HL60 and
HSB2 and 2.5 x 105 cells/mL for K562, Molt4 and Jurkat and placed in 6- well plates and
treated with simvastatin (1 or 4 µM), tipifarnib (0.1 or 1 µM) or their combinations for 72
hr. Cells incubated with 10 µL/mL DMSO were used as a control.
3. Cell viability assay and combination index calculation
A panel of six cell lines of varied leukemic origin including KG1, HL60, K562,
Jurkat, Molt4 and HSB2 was used to determine the cytotoxicity of simvastatin and
tipifarnib following single drug or combination treatment. Cells were placed in 96 well
plates at a density of 50 x 103 cells per well for KG1, HL60 and HSB2 or 25 x 103 cells
per well for K562, Molt4 and Jurkat in 100 µL of the appropriate growth medium. Cells
were incubated with increasing concentrations of simvastatin (0, 0.4 - 400 µM), tipifarnib
(0, 0.01 – 10 µM) or their combination at different concentrations for 72 hr at 37°C. At
the end of the incubation period, 10 μL of resazurin was added to each well and further
incubated for 3 hr at 37°C. Cell viability was determined by measuring the fluorescence
at 560 nm excitation wavelength and 590 nm emission wavelength using Molecular
Devices Spectramax M5 plate reader. Synergism between simvastatin and tipifarnib was
assessed using the combination index (CI) method of Chou and Talalay [162-164].
CI= d1/D1 + d2/D2
In this equation, D1 and D2 represent the doses of drug 1 and drug 2 alone,
required to produce x% effect, and d1 and d2 are the doses of drugs 1 and 2 in
combination required to produce the same effect. CI value < 1 indicates synergy while
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values = 1 or > 1 indicate additivity and antagonism, respectively. Experiments were
performed in triplicates.
4. Apoptosis Assay
Cells were harvested and washed with ice cold phosphate-buffered saline (PBS)
buffer, pH 7.2. Cell pellets were resuspended (1 x 106 cells/mL) in annexin binding buffer
(50 mM HEPES, 700 mM NaCl, 12.5 mM CaCl2, pH 7.4). To identify dead and apoptotic
cells, 1 µL propidium iodide (PI) and 5 µL Annexin V-FITC were added to each 100 µL of
cell suspension and samples were incubated for 15 min at room temperature. Samples
were diluted to 500 µL using annexin binding buffer before analysis using FACScan flow
cytometer (Becton Dickinson, Franklin Lakes, NJ). Cells that were positive for Annexin-V
but negative for PI were those in early stage apoptosis while cells positive for both
annexin-V and PI were in late stage apoptosis.
5. Cell cycle analysis
Cells were harvested and washed twice with ice cold PBS buffer. Cells were then
fixed in 3 mL of absolute ethanol overnight at 4ºC. Cells were washed twice with ice cold
PBS buffer and incubated with propidium iodide (100 µg/mL) and Ribonuclease A from
bovine pancreas (200 µg/mL) in the dark for 30 min at 37ºC. Processed samples were
kept at 4ºC and protected from light until analysis using a FACScan flow cytometer
(Becton Dickinson, Franklin Lakes, NJ).
6. Total and fractionated protein isolation
For total lysate preparation, cells were harvested after treatment and washed
twice with ice cold PBS. Cell pellets were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150
mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 1 mM EDTA, 0.1% SDS)
supplemented with Complete protease inhibitor cocktail and incubated for 30 min (4°C)
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on a rotating shaker. Cell lysates were then centrifuged at 1500 rpm for 2 min to remove
any particulates. Protein concentrations of membrane, cytosolic fractions and total cell
lysate were measured using the BCA protein assay.
For cytosolic and membrane protein fractions, cells were collected after
treatment and washed with ice cold PBS buffer. Cells (1x107) were lysed via sonication
for 15s in 200 µL lysis buffer I (1 mM EDTA, 20 mM Tris-HCl (pH 7.4)) supplemented
with Complete protease inhibitor cocktail. Lysates were centrifuged at 100,000 x g at 4°C
for 1 hr using an ultracentrifuge (OptimaMax, TLA55 rotor; Beckman Coulter). The
supernatant containing the soluble fraction (cytosolic fraction) was collected and the
pellet (membrane fraction) was then washed with 1 mL lysis buffer I twice, to remove
any remnant of the cytosolic fraction. The membrane pellet was solubilized in 50 µL lysis
buffer II (150 mM NaCl, 10 mM Tris-HCl, 5 mM EDTA, 1% Triton X-100) supplemented
with Complete protease inhibitor cocktail and then sonicated for 5s to solubilize any
particulate left in the buffer. Protein samples were stored at -20°C until analysis or were
processed immediately for immunoblotting.
7. Western blot analysis
The expression of total-PARP, cleaved PARP, cleaved caspases 3, 7 and 9 and
procaspases 3, 7 and 9, Bcl2, Mcl1, Bcl-xL, Bax, phospho ERK, total ERK, phospho
AKT, total AKT, RAS, calnexin

and GAPDH was evaluated in protein lysates or

subcellular fractions, as indicated. Protein samples were boiled at 95°C for 10 min with
NuPage LDS sample buffer and 0.1 M DTT. Protein electrophoresis was performed on
10% SDS-polyacrylamide gels (SDS-PAGE) at room temperature and proteins were
transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA) at
4°C. Membranes were blocked for 2 hr at room temperature with tris-buffered saline
(TBST) containing 0.05% (v/v) Tween-20 and supplemented with 5% (w/v) nonfat milk or
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bovine serum albumin. Membranes were incubated with primary antibodies overnight at
4°C at 1:1000 dilution. After washing with TBST, the membranes were probed with
HRP- conjugated secondary antibody at 1:2000 dilution (Cell Signaling Technology Inc.)
for 1 hr at room temperature. Following washes with TBST, protein bands were
visualized by enhanced ECL (Thermo Fisher Scientific, Rockford, IL) using the Kodak
Image Station 2000 MM (Eastman Kodak, Rochester, NY).
8. Statistical analysis
Data are reported as mean values ± SD and analyzed statistically with one-way
ANOVA followed by Turkey’s post-hoc test. P values ≤ 0.05 were considered significant.
C. Results
1. Simvastatin and tipifarnib combination has a synergistic antiproliferative
effect in leukemia cell lines
To evaluate the potential for synergy between simvastatin and tipifarnib we
treated KG1, HL60, K562, Jurkat, Molt4 and HSB2 cell lines with either drug alone, to
determine the respective IC50 (Table A.1 and A.2, Figure A.1 and A.2), and then with
different concentrations of simvastatin (1 and 4 µM ) and tipifarnib (0.05, 0.1, 0.5 and 1
µM) in combination. Cell viability was measured after 72 hr of treatment using a
fluorometric cell proliferation assay as described under methods. Synergism was
assessed by calculating CI values, which is based on the mathematical model described
by the Chou and Talalay [162-164]. As shown in Figure 5.1, with the exception of the
KG1 cells the combination of simvastatin and tipifarnib was synergistic at all
concentrations. Overall, simvastatin at high dose yielded higher fractional effect (FE) in
combination with tipifarnib, relative to its lower dose. This effect was more substantial in
HL60 cells for both CI and FE values. These results indicate that the combination of
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simvastatin and tipifarnib synergistically enhanced the cytotoxic effects in various
leukemia cell lines.
2. The synergistic effects of simvastatin/tipifarnib are mediated by apoptosis
To determine if the combination of simvastatin/tipifarnib was cytotoxic, we
investigated whether the reduced cell viability was attributed to apoptosis. Leukemia
cells were treated with simvastatin (1 or 4 µM) and tipifarnib (0.1 or 1 µM) concentrations
alone or in combination for 72 hr. Subsequently, western blot analysis was performed to
analyze the activation of the caspase cascade. As shown in Figure 5.2A, proteolytic
cleavage of caspase 3 and 7 to their active forms triggered the apoptotic process
through the cleavage of other important intracellular substrates such as poly
(ADPribose) polymerase (PARP), which is involved in DNA repair. These results were
consistent in all leukemia cell lines tested. However, caspase 7 was only activated in
Jurkat, Molt4 and HSB2 cells. Moreover, we examined caspase 9 activation (cleavage of
caspase 9), which acts upstream of caspase 3 and 7, using western blot analysis.
Elevated expression of cleaved caspase 9 was observed in K562, Jurkat, Molt4 and
HSB2 cells. HL 60 cells showed no expression of both the full length and cleaved forms
of caspase 7 and 9 and PARP. Conversely, KG1 cells were more resistant to
simvastatin/tipifarnib with no signs of caspase cascade activation or PARP cleavage.
In fact, several reports suggest the importance of the antiapoptotic and
proapoptotic Bcl-2 family proteins in regulating cell survival and apoptosis [165-169]. To
better understand the apoptotic effect of simvastatin/tipifarnib, we also examined the
expression of Bcl2 family proteins in leukemia cells treated with simvastatin and tipifarnib
alone or in combination for 72hr using western blot analysis. As shown in Figure 5.2B,
combined treatment of simvastatin and tipifarnib did not substantially alter the
expression of either antiapoptotic (e.g., Bcl2 and Bcl-xL) or proapoptotic (e.g., Bax)
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proteins. However, simvastatin/tipifarnib resulted in a significant reduction on the
expression of the antiapoptotic Mcl1 protein in all leukemia cells except KG1.
To further confirm the apoptosis inducing effect of simvastatin/tipifarnib, Annexin
V-FITC and PI analysis was performed on a subset of cells. The HL60 and Jurkat cells
were treated with simvastatin (1 or 4 µM) and tipifarnib (0.1 or 1 µM) alone or in
combination. As shown in Figure 5.2C and Figure 5.2D, combined treatment of
simvastatin and tipifarnib showed a significant increase in early (AnnexinV+/PI-) and late
(Annexin V+/PI+) apoptosis in both cell lines, compared to control and single treatments.
Together these findings indicate that the synergistic interaction between simvastatin and
tipifarnib in human leukemia cells is mediated by apoptosis. Also, KG1 was shown to be
more resistant to this combination than other leukemia types.
3. Synergistic cytotoxicity of simvastatin/tipifarnib in leukemia cells is not
associated with cell cycle arrest
Since the cell proliferation assay cannot distinguish between apoptotic and
arrested cells, we examined whether cell cycle arrest is contributing to the decrease in
cell viability following simvastatin/tipifarnib exposure. Leukemia cells including KG1,
HL60, K562 and HSB2 were treated with simvastatin (4 µM) and tipifarnib (1 µM) alone
and in combination for 72hr. After treatment, cell cycle distribution was assessed using
flow cytometry. The distribution of the cell cycle phases (G1, S and G2/M) showed no
significant changes after treatment relative to control in all leukemia cells tested (Figure
5.3). These results suggest that the synergetic interaction of simvastatin/tipifarnib is
cytotoxic and not cytostatic.
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4. Co-Treatment of simvastatin and tipifarnib disrupts the localization of RAS
in the cell membrane
The RAS GTPases are important mediators of cell signaling pathways involved in
the survival and proliferation of cancer cells. FTI drugs were developed to prevent the
farnesylation of RAS and thus inhibit its membrane incorporation and ultimately the RAS
mediated signaling. As reported previously, the limited efficacy of tipifarnib, as well as
that of other FTIs, may be attributed to the continued signaling of RAS by alternative
isoprenylation (geranylgeranylation). Mounting evidence suggests that the anticancer
activity of simvastatin is mediated by its capacity to disrupt the geranylgeranylation of
small G-protein, primarily RHO proteins [59, 75, 79]. We therefore reasoned that
coadministration of simvastatin and tipifarnib could disrupt the RAS prenylation process
and its membrane association through blocking both the farnesylation and the alternative
geranylgeranylation pathways. Leukemia cells were treated with simvastatin (4µM) and
tipifarnib (1µM) alone or in combination for 72hr and cells subjected to a fractionation
procedure to isolate the membrane and the cytosolic protein fractions. Western blot
analysis was performed to determine RAS location in both fractions. Interestingly,
simvastatin/tipifarnib robustly inhibited the membrane association of RAS with its
subsequent sequestration into the cytosol, Figure 5.4. This effect was not observed in
KG1 cells where RAS localization in the cell membrane did not change upon treatment
with the combination compared to the control and single treatments. Overall, these
findings indicate that simvastatin in the presence of tipifarnib disrupts membrane
association of RAS and most likely results in loss of RAS function because of its inability
to associate with membrane bound effectors.
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5. Simvastatin/tipifarnib downregulates the ERK downstream signaling in
human leukemia cell lines.
It is well known that RAS activation is a crucial step for several cytoprotective
and stress related signaling pathways. Therefore, we examined the effect of
simvastatin/tipifarnib on the phosphorylation status (activity) of two main RAS
downstream signaling pathways; ERK and AKT pathways. As shown in Figure 5.5, a 24
hr treatment of simvastatin/tipifarnib significantly decreased the phosphorylation of ERK
in three of the tested leukemia cell lines including HL60, K562 and HSB2. Both KG1 and
Jurkat cells showed no expression of the phosphorylated form of ERK. In addition, only
Jurkat cells showed high levels of phosphorylated AKT. Interestingly, upon treatment
with simvastatin alone or in combination the AKT phosphorylation was abolished. This
result indicates that downregulation of the ERK signaling is most likely because of the
effect of simvastatin/tipifarnib in disrupting the upstream RAS membrane localization and
its subsequent deactivation.
6. Addition of mevalonate and isoprenoids prevents simvastatin/tipifarnib
induced apoptosis and reverses the disrupted RAS isoprenylation
To further investigate whether blocking the isoprenylation routes is responsible
for the apoptotic effect of simvastatin/tipifarnib, leukemia cells were treated with
mevalonate and isoprenoids (FPP and GGPP) in the presence of simvastatin/tipifarnib.
Annexin V apoptosis assay and western blot analysis of caspase 3 and Mcl1 were
employed to assess apoptosis. The Annexin V assay revealed that the apoptotic effect
of simvastatin/tipifarnib was reversed by the addition of mevalonate, FPP or GGPP in
HL60 cells (Figure 5.6A and B). Similarly, western blot analysis, in Figure 5.6C, indicated
that caspase 3 activation (cleaved caspase 3) and Mcl1 downregulation induced by
simvastatin/tipifarnib, in both K562 and HSB2 cells, were reversed by the addition of
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mevalonate, FPP or GGPP. On the other hand, the effect of this combination on RAS
disruption from the membrane was reversed by the addition of mevalonate and GGPP
and partially by FPP (Figure 5.6D). These findings indicate that simvastatin/tipifarnib is
mediating its apoptotic effect and RAS membrane disruption through the blocking of both
the farnesylation and the geranylgeranylation pathways.
D. Discussion
Aberrant activation of the oncogenic RAS signal transduction is commonly
observed in hematological malignancies. RAS mutations have been reported in 30% of
leukemia, most frequently acute leukemia. FTIs were initially developed to inhibit RAS
activation through blocking its farnesylation process. Despite the encouraging preclinical
results, FTIs showed limited activity in clinical trials. This is thought to be due to the
ability of RAS to get activated through the geranylgeranylation pathway, which acts
alternatively to the farnesylation pathway once FTIs are administered. This escape
mechanism was only noticed in K-RAS and N-RAS isoforms, which are commonly
mutated in solid tumors and leukemia, respectively [158]. Blocking this alternative
prenylation pathway is an attractive strategy to evade the resistance to FTIs. Here we
report that simvastatin was able to augment the cytotoxicity of tipifarnib in a panel of
leukemia cells through blocking the alternative geranylgeranylation pathway of RAS.
Our data show that simvastatin significantly increased the cytotoxic effect of
tipifarnib in the different leukemia cells tested. Results from both cell viability and
apoptotic assays indicate that leukemia cells were differentially affected by the
simvastatin/tipifarnib combination. The increased sensitivity to this combination was
more significant in HL60 compared to other leukemia cells tested whereas KG1 cells
were more resistant with no signs of apoptosis. Our finding was in agreement with
previous work, which demonstrated that KG1 is one of the insensitive cell lines that
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required higher doses of simvastatin or tipifarnib relative to other leukemia cell lines
[170]. Moreover, heterogeneity in response to statins and FTIs in primary CD34+ AML
cells has been reported recently [171].
In our studies, we employed AML, ALL and CML cells. With the exception of one
AML cell line (KG1) the simvastatin/tipifarnib combination was synergistic in all other cell
lines. However, the observed synergy appears to be independent of RAS mutations.
Specifically, HL60 (N-RAS mutation, c.182A>T), Molt4 and HSB2 cells (N-RAS mutation,
c.34G>T) and K562 and Jurkat cells (N- RAS wild type) were all sensitive, while KG1 (NRAS mutation, c.35G>A) was resistant. An alternative explanation for the antagonism
observed in the KG1 cells could be the presence of efflux transporters, such as P-gp and
BCRP, which could be potentially effluxing the lactone and carboxylate species,
respectively. However, those proteins were not found in these cells by Western blot
analyses (data not shown). This does not preclude the presence of other transporters
that may limit the accessibility of the simvastatin carboxylate form to the cancer cell. For
example, MRP1 is an efflux transporter that is ubiquitously expressed and primarily
transports anionic compounds. Additionally, further studies will be required to assess if
the KG1 resistance is attributed to deregulated function of the mevalonate pathway.
Here we determined that the observed synergy following combination treatment
was due to increased apoptosis. The balance between antiapoptotic (e.g. Bcl-2, Mcl-1
and Bcl-xL) and proapoptotic (e.g. Bax and Bad) proteins regulates the release of
cytochrome c from the mitochondria into the cytosol, which will lead to the activation of
the caspase cascade and the induction of apoptosis. In this study, we demonstrate that
the simvastatin/tipifarnib combination initiates apoptosis through the downregulation of
Mcl1 protein. Mcl-1 is an anti-apoptotic member of the Bcl-2 protein family that prevents
apoptosis

by forming

heterodimers
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with

proapoptotic

Bcl-2

family members.

Downregulation of Mcl1 protein allows the proapoptotic Bcl2 proteins to initiate
mitochondrial collapse and subsequent release of cytochrome c into the cytosol where it
activates the apoptotic caspase cascade.

Conversely, our results show that Bax

expression was unchanged by treatment in all cell lines that expressed it.
In fact, RAS plays a central role in activating several downstream effectors that
are known to regulate different cell functions including cell growth, survival and
differentiation. Therefore, therapeutic targeting of RAS signaling pathways has become
a major endeavor in cancer therapy. Our results demonstrated that disrupting RAS
membrane localization, by simvastatin/tipifarnib cotreatment, significantly decreased
ERK phosphorylation in the cell lines tested. This finding is in line with previous work,
which demonstrated the disruption of RAS/ERK signaling in multiple myeloma cells
treated with FTI/lovastatin [172]. In general, our results indicate that RAS/MEK/ERK
pathway might be involved in simvastatin/tipifarnib induced cytotoxicity. However, the
lack of the basal level of ERK activity in Jurkat cells, which are sensitive to this
combination, may indicate the involvement of other RAS downstream pathways.
Conversely, the insensitive cell line KG1 showed no inhibition of RAS isoprenylation
when treated with simvastatin/tipifarnib combination. Previous report has shown that
higher concentrations of simvastatin (100 µM) were required to block the isoprenylation
of RAS in resistant AML cell lines [170].
On the other hand, reversal of simvastatin/tipifarnib combination induced
apoptosis by mevalonate, FPP and GGPP was notably consistent in the sensitive
leukemia cells. This observation confirms that prenylation pathways are the cellular
targets of this combination. In line with this finding, RAS membrane disruption was also
abrogated by the addition of mevalonate and GGPP and partially by FPP. This partial
effect of FPP could be attributed to the higher binding affinity of tipifarnib to FTase,

79

therefore higher FPP concentrations might be required to completely reverse the effect
of tipifarnib in this combination. Although, the disruption of RAS prenylation was clearly
seen upon treatment with simvastatin/tipifarnib combination and was strongly correlated
with cellular response, RAS as an exclusive target for this combination is still
questionable. Several reports suggested that RAS may not be the only target for FTI
treatment and other elusive targets may be involved [173]. The wide pool of proteins that
undergo prenylation makes it difficult to identify a true therapeutic target for
simvastatin/tipifarnib. Nonetheless, the ability of GGPP and FPP to rescue the effect of
simvastatin/tipifarnib combination on the membrane localization of RAS demonstrates
the role of the alternative prenylation as a mechanism of resistance to tipifarnib
monotherapy.
Furthermore, the use of simvastatin as anticancer agent was limited by the high
doses required to mediate its antitumor activity. However, in our study, simvastatin was
shown to induce apoptosis in combination with tipifarnib at lower concentrations, as low
as 1µM. It is interesting to note that simvastatin, given at maximum tolerated dose
(7.5mg/kg, twice daily) to leukemia patients, was found to achieve plasma levels
comparable to those used in our study (Chapter 4).
In summary, the results obtained in this study suggest that synergistic cytotoxic
effect of simvastatin/tipifarnib combination is, at least in part, due to the disruption of
RAS membrane localization. Reversal of such effect by the addition of GGPP and FPP
indicates the role of alternative geranylgeranylation as an escape mechanism for RAS
activation in the presence of tipifarnib. However, such preliminary evidence of in vitro
data needs further in vivo investigation.
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Figure 5.1. Simvastatin synergistically potentiates tipifarnib mediated lethality in human
leukemia cells. Leukemia cell viability was determined following combination treatment
with simvastatin (1 or 4 µM) and tipifarnib (0.05, 0.1, 0.5 or 1 µM) for 72 hours.
Fractional effect (FE) values were determined by comparing results with those of
untreated controls. Open and closed circles represent 1 and 4 µM simvastatin treated
sets, respectively. Numbers from 1 to 4 denote tipifarnib concentrations in ascending
order. Results are the mean of 3 independent experiments.
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Figure 5.2. Combined exposure of leukemia cells to simvastatin and tipifarnib induces
apoptosis through caspase activation and downregulation of Mcl1. Leukemia cells were
treated for 72 hours with simvastatin and tipifarnib at concentrations indicated, either
alone or in combination. At the end of the incubation period, cells were lysed and
western blot analysis was performed to monitor the cleavage of caspases and PARP (A)
and the expression of BCL2 family proteins (B). GAPDH was used as a loading control
to ensure equivalent loading. Alternatively, HL60 and Jurkat cells were treated with
simvastatin (4 µM) and tipifarnib (1 µM) alone and in combination for 72hr. Cells were
then costained with Annexin and PI with subsequent flow cytometric analysis. A
representative dot-plot is shown for each condition (C). AnnexinV+/PI- stained cells in
the bottom right quadrant represent early apoptotic cells whereas late apoptotic or
necrotic cells are located in the upper right quadrant with Annexin+/PI+ staining. In panel
(D), representative figures of AnnexinV/PI staining of HL60 and Jurkat cells showing the
sum of the percentages of early and late apoptotic cells. Results represent means of 3
independent experiments. Data are presented as mean ± SD. *, P > 0.05, significantly
greater than values for cells exposed to simvastatin or tipifarnib alone. SIM, simvastatin.
TIP, tipifarnib.
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Figure 5.3. Simvastatin/tipifarnib does not induce cell cycle arrest in leukemia cells.
Leukemia cells were treated for 72 hours with simvastatin (4 µM) and tipifarnib (1 µM),
alone and in combination, before being stained with PI and analyzed by flow cytometry.
SIM, simvastatin. TIP, tipifarnib
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Figure 5.4. Simvastatin/tipifarnib alters subcellular localization of RAS in human
leukemia cells. Leukemia cells were treated with simvastatin (4 µM) and tipifarnib (1
µM), alone and in combination for 72hrs. Cytosolic and membrane fractions were
prepared and western blot analysis was performed as described in the method section
using the indicated antibodies. Calnexin was used as a membrane marker, whereas
GAPDH is a marker of the cytosolic fraction. SIM, simvastatin. TIP, tipifarnib.
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Figure 5.5. Co-treatment of simvastatin and tipifarnib blocks ERK phosphorylation in
human leukemia cells. Upon treatment with simvastatin (4 µM) and tipifarnib (1 µM),
alone and in combination for 24hr, leukemia cells were processed for western blot
analysis using the indicated antibodies. GAPDH was used as a loading control. SIM,
simvastatin. TIP, tipifarnib.
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Figure 5.6. Depletion of prenyl substrates by simvastatin/tipifarnib is associated with
apoptosis induction, caspase activation, Mcl1 downregulation and RAS membrane
disruption. HL60 cells were cotreated with simvastatin (4 µM) and tipifarnib (1 µM) in the
presence of mevalonate (200 µM), farnesyl pyrophosphate (10 µM) and geranylgeranyl
pyrophosphate (10 µM). After 72 hour incubation, cells were harvested and costained
with Annexin V/PI with subsequent flow cytometric analysis. A representative dot-plot
and bar-figure were shown for each condition (A) and (B), respectively. Alternatively,
K562 and HSB2 cells were treated similarly and then processed for western blot analysis
to assess the expression of caspase 3 and Mcl1 (C). GAPDH was used as a loading
control. Under the same conditions, HL60, K562 and HSB2 cells were processed for
western blot analysis to monitor the expression of RAS in both the cytosolic and
membrane fractions (D). Calnexin was used as a membrane marker, whereas GAPDH is
a marker of the cytosolic fraction. Results represent means of 3 independent
experiments. Data are presented as mean ± SD. *, P > 0.05, significantly lower than
values for cells exposed to simvastatin-tipifarnib combination. SIM, simvastatin. TIP,
tipifarnib.
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Chapter 6 : General Discussion
Statins are inhibitors of 3-hydroxy-3methylglutaryl (HMG) Co-A reductase that
prevent cardiovascular diseases and lower LDL cholesterol. In recent years, increasing
evidences from in vitro and in vivo studies have established the antitumor activity of
statins, independent of cholesterol reduction. Besides their preclinical activity, statins
have favorable safety profile and are available orally at a relatively inexpensive cost.
Therefore, investigators were tempted to bring statins into the clinic for cancer therapy.
However, clinical experience with high dose statins in cancer patients has reported
unsuccessful outcomes [92, 95-97]. This thesis discusses the clinical utility and
prospects of statins in cancer therapy.
As a part of the clinical development of high dose simvastatin in cancer patients,
understanding the pharmacokinetics of this drug at high doses was important. Our
pharmacokinetic study is the first to examine simvastatin concentrations in both plasma
and tumor cells after high dose administration in leukemia patients. In fact, simvastatin at
maximum tolerated dose (7.5 mg/kg, twice daily) achieved higher plasma concentrations
(0.08-2.2 µM) relative to a typical dose (40mg) which has a peak plasma concentration
of 0.02-0.08 µM (10-34 ng/mL). However, the high plasma concentrations achieved are
still lower than those found to be effective in vitro. These insufficient levels of simvastatin
are the most likely explanation of the limited efficacy of high dose simvastatin observed
in previous clinical studies [96, 97]. These low levels of simvastatin are mainly attributed
to the extensive first pass extraction of simvastatin that hinders the drug reaching the
systemic circulation at sufficient concentrations. Overall, this poor delivery process of
statins to the circulation urges further exploration of different strategies to improve
bioavailability and consequent clinical activity.
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Most of the clinical studies assessing the antitumor activity of high dose statins,
have no rationale for the choice of statins. The statin member that is most effective and
shows favorable clinical profile have yet to be determined. Currently, there are seven
FDA approved statins in the market that possess the same mechanism of action;
however, they differ in terms of their chemical structures, pharmacokinetic profiles and
potencies. In terms of efficacy, preclinical studies have demonstrated that lipophilic
statins (e.g. lovastatin, simvastatin, atorvastatin, fluvastatin and pitavastatin) have better
antitumor activity relative to hydrophobic statins (e.g. pravastatin and rosuvastatin) [174177], which is logical since lipophilic statins are more accessible to the tumor cells. On
the other hand, the low systemic bioavailability of statins is considered a major barrier
that may impede their clinical activity as anticancer agents. In this regard, both
simvastatin and lovastatin show the lowest bioavailability (below 5%) relative to other
statin members; yet, they were the most studied statins in clinical trials. Another
disadvantage of simvastatin and lovastatin is their fast elimination with half-life less than
three hours. Moreover, simvastatin and lovastatin are substrates for CYP3A4
metabolizing enzyme [178] that may limit their use in combination with other anticancer
agents, if a CYP3A4 interaction exists. In view of the poor pharmacokinetic profile of
both simvastatin and lovastatin, they are unlikely to be considered as an optimal statin
model for cancer therapy. Therefore, achieving higher bioavailability for prolonged period
of time is vital for statins in order to score better distribution in the tumor and
subsequently to attain better efficacy. Fluvastatin, has shown improved bioavailability
(10-35%) and limited CYP3A4 metabolism; however, the very short half-life of fluvastatin
(0.5 – 2.3 hr) is a major pitfall that may hold back its clinical development as an
anticancer therapy. Conversely, pitavastatin, a lipophilic statin recently approved by the
FDA, shows superior systemic bioavailability (80%) relative to other statins as well as
longer half-life (11 hours) and limited CYP450 metabolism [178]. Despite of the very few
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studies that have evaluated the antitumor activity of pitavastatin, its favorable
pharmacokinetic profile makes it a promising candidate that warrants further evaluation
in cancer therapy.
With respect to statin dose, there has been a debate in the last decade about the
optimal dosage regimen of statins in cancer therapy. In view of the clinical experience of
statins in cancer treatment, most of clinical studies have favored continuous
administration of low dose statins over intermittent high dose regimens in terms of
safety. Moreover, continuous low dose statin was thought to achieve better efficacy
through a sustainable blockage of the mevalonate pathway. In fact, most of these
studies have evaluated the significance of using statins at typical doses as an adjuvant
treatment in cancer; yet, outcomes turned to be controversial. Of note, high dose statins
were evaluated in clinical studies as a sole therapy not in combination with standard
therapy which is the case in low dose statins; thus, it is not clear whether low-dose
statins is better than high doses in terms of efficacy.
The lack of clinical benefits of high dose statins in previous studies does not
preclude that statins at high dose could be useful in combination with other anticancer
agents. Several preclinical studies have shown the ability of statins to interact
synergistically with various antitumor treatments [100-104]. Recently, a phase II study
has evaluated high dose simvastatin in combination with vincristine (0.4 mg), adriamycin
(9 mg/m2), and dexamethasone 40mg orally (VAD) in a sequential administration [97].
Addition of high dose simvastatin showed no response that could be attributed to the
treatment strategy (sequential versus simultaneous) as well as the short half-life of
simvastatin. However, in vivo treatment with high dose simvastatin for 7 consecutive
days in leukemia patients displayed an increase in the in vitro chemosensitivity of their
AML cells [179].
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In recent years, the development of molecular targeted therapeutics is dramatically
evolving over conventional cytotoxic drugs. Many targeted agents that modulate specific
oncogenic proteins have been approved or still under development with the hope to
achieve better anticancer activity and fewer side effects. However, the ability of the
tumor to confer resistance (intrinsic or acquired) against these molecular targeted agents
is common. Thus, combination therapies become a well-established principle in cancer
therapy to circumvent cancer resistance. In this thesis, simvastatin was used in
combination with tipifarnib to evade cancer resistance developed against tipifarnib when
used alone. Tipifarnib is a farnesyl transferase inhibitor that was initially developed to
target RAS farnesylation. However, when cells were treated with tipifarnib, K-RAS and
N-RAS become geranylgeranylated and remain fully functional. Our study showed that
simvastatin in combination with tipifarnib, at clinically achievable concentrations,
displayed a synergistic interaction in leukemia. This synergistic combination was based
on a mechanistic rationale that targets farnesylation pathway of RAS as well as its
alternative geranylgeranylation pathway. Here we demonstrate that inhibition of both
prenylation pathways, by combining simvastatin with tipifarnib, induces synergistic
lethality that was not attained by the inhibition of each prenylation pathway separately.
Although our study was limited to the in vitro setting and to established cancer cell lines,
recent study have demonstrated that simvastatin was able to inhibit geranylgeranylation
pathway in primary AML cells at concentrations similar to those used in our study [179].
Generally, these in vitro findings warrant further investigation of high dose statins in
combination with tipifarnib in leukemia patients. In addition, given the fact that this
combination was able to knockdown RAS from the cellular membrane, further
exploration of this combination in other cancer models that harbor K- RAS mutation such
as pancreatic, colorectal and non-small cell lung cancers is encouraged.
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It is also worth noting that this combination showed variable response among the
different leukemia cell lines where AML cell line (HL-60) was the most sensitive one
toward this combination. This finding is supported by previous work that has reported
similar heterogeneity in response among group of AML cell lines toward simvastatin,
tipifarnib or GGTI-298 when they were used separately [170]. The differential sensitivity
of AML cells was attributed to the difference in interference with prenylation pathways.
This was in line with our finding that simvastatin/tipifarnib combination was shown to
disrupt RAS isoprenylation in the sensitive HL-60 cells relative to KG1 cells which were
more resistant. Interestingly, this heterogeneity in response was observed in primary
AML cells when treated with simvastatin or FTI/lovastatin. However, further investigation
is needed to unravel the molecular basis of this differential behavior among AML cells
and to find whether it can be exploited in the identification of leukemia patient population
who are most likely to respond for this given combination.
In conclusion, this thesis provides insights into the clinical feasibility of simvastatin
and the new approaches of its use in cancer therapy. Using LC-MS/MS analytical tool,
we have measured simvastatin lactone and carboxylate levels in both plasma and
PBMCs collected from chronic lymphocytic leukemia patients after high dose
administration. Despite the limited number of patients enrolled in this pilot trial, our data
indicate that simvastatin at high doses showed insufficient plasma and tumor
concentrations which are below those found effective in-vitro. This finding discourages
the use of high dose statins as a sole therapy in cancer patients, and that, further
exploration of strategies to improve its clinical activity is required. One promising
approach is considered in this thesis which is the combination of simvastatin with other
anticancer agents that may show synergy. Our studies demonstrated a synergistic
interaction of simvastatin and tipifarnib combination which might be mediated by the
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RAS/MEK/ERK pathway disruption. These promising preclinical results warrant further
investigation in other cancer models and in animal models as a step toward future
clinical application.

Copyright © Tamer Ahmed 2013
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APPENDICES
Appendix A: Evaluation of the antiproliferative effect of simvastatin and tipifarnib in
leukemia cell lines.
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C
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Figure A.1. Dose response curve of simvastatin in human leukemia cell lines. Cell lines,
KG1 (A), HL-60 (B), K562 (C), Molt4 (D), Jurkat (E) and HSB2 (F) were treated for 72
hrs with different concentrations of simvastatin (0-400µM). At the end of the incubation
period, 10 μL of resazurin was added to each well and further incubated for 3 hr at 37°C.
Cell viability was determined by measuring the fluorescence at 560 nm excitation
wavelength and 590 nm emission wavelength using Molecular Devices Spectramax M5
plate reader. Experiments were performed in triplicates.
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Figure A.2. Dose response curve of tipifarnib in human leukemia cell lines. Cell lines,
KG1 (A), HL-60 (B), K562 (C), Molt4 (D), Jurkat (E) and HSB2 (F) were treated for 72
hrs with different concentrations of simvastatin (0-10µM). At the end of the incubation
period, 10 μL of resazurin was added to each well and further incubated for 3 hr at 37°C.
Cell viability was determined by measuring the fluorescence at 560 nm excitation
wavelength and 590 nm emission wavelength using Molecular Devices Spectramax M5
plate reader. Experiments were performed in triplicates.
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Table A.1. IC50 values (µM) of simvastatin in leukemia cell lines (n=3).

IC50 Values (95%CI)
Cell line

Sample# 1

Sample# 2

Sample# 3

Mean (SD)

KG1

79.29
(61.49 to 102.2)

31.03
(22.52 to 42.75)

34.01
(29.79 to 38.84)

48.1 (27.0)

HL60

17.33
(14.83 to 20.25)

9.419
(8.202 to 10.82)

12.17
(10.57 to 14.02)

12.9 (4.0)

K562

15.14
(10.40 to 22.04)

10.02
(7.911 to 12.70)

5.938
(4.692 to 7.515)

10.3 (4.6)

Molt4

12.59
(8.204 to 19.33)

11.50
(8.793 to 15.04)

23.89
(17.26 to 33.05)

15.9 (6.8)

Jurkat

20.98
(15.58 to 28.26)

12.31
(10.32 to 14.69)

10.96
(9.695 to 12.40)

14.7 (5.4)

HSB2

39.08
(26.54 to 57.56)

23.47
(20.49 to 26.88)

28.34
(23.22 to 34.59)

30.2 (7.9)

Table A.2. IC50 values (µM) of tipifarnib in leukemia cell lines (n=3).

IC50 Values (95%CI)
Cell line

Sample# 1

Sample# 2

Sample# 3

Mean (SD)

KG1

0.878
(0.558 to 1.383)

0.287
(0.169 to 0.487)

0.169
(0.085 to 0.337)

0.44 (0.37)

HL60

0.208
(0.135 to 0.322)

0.414
(0.266 to 0.645)

0.650
(0.400 to 1.057)

0.42 (0.22)

K562

1.094
(0.593 to 2.015)

1.254
(0.798 to 1.970)

0.511
(0.311 to 0.842)

0.95 (0.38)

Molt4

1.688
(1.012 to 2.814)

1.187
(0.659 to 2.136)

1.201
(0.720 to 2.004)

1.35 (0.28)

Jurkat

1.019
(0.619 to 1.676)

0.513
(0.358 to 0.736)

0.936
(0.660 to 1.329)

0.81 (0.26)

HSB2

0.696
(0.483 to 1.003)

1.041
(0.774 to 1.399)

0.765
(0.604 to 0.970)

0.83 (0.18)
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